

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number
WO 2005/009968 A1

(51) International Patent Classification⁷: **C07D 215/38**,
215/48, 403/04, A61K 31/47, 31/4709, 31/497, A61P
9/10, 11/00, 29/00

(21) International Application Number:
PCT/SE2004/001144

(22) International Filing Date: 21 July 2004 (21.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0302139-1 28 July 2003 (28.07.2003) SE

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FORD, Rhonan** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **THOMPSON, Toby** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB). **WILLIS, Paul** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINOLINE DERIVATES AND THEIR USE IN THERAPY



(57) Abstract: The invention provides compounds of formula (I) wherein n, p, q, X, R¹, R², R³, R⁴, R⁵ and R⁶ are as defined in the specification; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Quinoline derivates and their use in therapy

The present invention relates to certain heteroaryl amide derivatives, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.


5

The P2X₇ receptor (previously known as P2Z receptor), which is a ligand-gated ion channel, is present on a variety of cell types, largely those known to be involved in the inflammatory/immune process, specifically, macrophages, mast cells and lymphocytes (T and B). Activation of the P2X₇ receptor by extracellular nucleotides, in particular adenosine triphosphate, leads to the release of interleukin-1 β (IL-1 β) and giant cell formation (macrophages/microglial cells), degranulation (mast cells) and proliferation (T cells), apoptosis and L-selectin shedding (lymphocytes). P2X₇ receptors are also located on antigen-presenting cells (APC), keratinocytes, salivary acinar cells (parotid cells), hepatocytes and mesangial cells.

15

It would be desirable to make compounds effective as P2X₇ receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases, in the aetiologies of which the P2X₇ receptor may play a role.

20 The present invention provides a compound of formula



or a pharmaceutically acceptable salt or solvate thereof, wherein

p is 0, 1 or 2;

25 each R¹ independently represents halogen or C₁-C₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁-C₆ alkoxy;

X is C(O)NH or NHC(O);

n is 1, 2, 3, 4 or 5;

within each grouping, CR^5R^6 , R^5 and R^6 each independently represent hydrogen, halogen, phenyl or C_1 - C_6 alkyl, or R^5 and R^6 together with the carbon atom to which they are both attached form a C_3 - C_8 cycloalkyl ring;

- 5 R^2 represents an unsaturated 4- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, $-COOR^{13}$, hydroxyl, $-NR^{14}R^{15}$, $-CONR^{16}R^{17}$, $-SO_2NR^{18}R^{19}$, $-NR^{20}SO_2R^{21}$, C_1 - C_6 alkyl, C_1 - C_6 alkylcarbonyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylcarbonyloxy, C_1 - C_6 alkoxy carbonyl, C_1 - C_6 hydroxyalkyl and $-S(O)_mC_1$ - C_6 alkyl where m is 0, 1 or 2;

R^3 represents hydrogen or a group $-R^7$, $-OR^7$, $-SR^7$ or $-NR^7R^8$;

q is 0, 1 or 2;

each R^4 independently represents halogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

- 15 R^7 and R^8 each independently represent hydrogen, C_1 - C_{10} alkyl, C_3 - C_8 cycloalkyl or a saturated or unsaturated 3- to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the alkyl, cycloalkyl and heterocyclic ring system each being optionally substituted with at least one substituent selected from halogen, hydroxyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_1 - C_6 hydroxyalkyl, C_1 - C_6 hydroxyalkoxy, C_1 - C_6 alkoxy carbonyl, C_3 - C_8 cycloalkyl, $-NR^9R^{10}$, $-COOR^{22}$, $-CONR^{23}R^{24}$, $-SO_2NR^{25}R^{26}$, $-NR^{27}SO_2R^{28}$ and ZR^{68} or

- alternatively, R^7 and R^8 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur and that optionally further comprises a bridging group, the heterocyclic ring being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_1 - C_6 hydroxyalkyl, C_1 - C_6 hydroxyalkoxy, C_1 - C_6 alkoxy carbonyl, C_3 - C_8 cycloalkyl, $-NR^{11}R^{12}$, $-COOR^{29}$, $-CONR^{30}R^{31}$, $-SO_2NR^{32}R^{33}$, $-NR^{34}SO_2R^{35}$, $Z'R^{69}$, $(CH_2)_{1-6}NR^{70}R^{71}$, SO_2R^{72} ,
- 25

$\text{NR}^{73}\text{CONR}^{74}\text{SO}_2\text{R}^{75}$ or $\text{M}(\text{CH}_2)_{1-6}\text{COOR}^{76}$ wherein M represents a bond, O, S, SO, SO_2 , and a group $>\text{NR}^{77}$;

R^9 and R^{10} each independently represent hydrogen or a C_1 - C_6 alkylcarbonyl, C_2 - C_7 alkenyl or C_1 - C_7 alkyl group, each group being optionally substituted with at least one substituent selected from hydroxyl, $-\text{NR}^{36}\text{R}^{37}$, $-\text{COOR}^{38}$, $-\text{CONR}^{39}\text{R}^{40}$, $-\text{SO}_2\text{NR}^{41}\text{R}^{42}$, $-\text{NR}^{43}\text{SO}_2\text{R}^{44}$, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_1 - C_6 alkoxy carbonyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system in turn being optionally substituted with at least one substituent selected from halogen, hydroxyl, oxo, carboxyl, cyano, C_1 - C_6 alkyl and C_1 - C_6 hydroxyalkyl, or

alternatively, R^9 and R^{10} may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur, the heterocyclic ring being optionally substituted with at least one substituent selected from $-\text{OR}^{54}$, $-\text{NR}^{55}\text{R}^{56}$, $-(\text{CH}_2)_t\text{NR}^{57}\text{R}^{58}$ where t is 1, 2, 3, 4, 5 or 6, $-\text{COOR}^{59}$, $-\text{CONR}^{60}\text{R}^{61}$, $-\text{SO}_2\text{NR}^{62}\text{R}^{63}$, $-\text{NR}^{64}\text{SO}_2\text{R}^{65}$, C_1 - C_6 hydroxyalkyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio, C_1 - C_6 alkoxy carbonyl and $\text{Z}'\text{R}^{80}$;

R^{11} and R^{12} each independently represent hydrogen or a C_1 - C_6 alkylcarbonyl, C_1 - C_6 alkoxy carbonyl, C_2 - C_7 alkenyl or C_1 - C_7 alkyl group, each group being optionally substituted with at least one substituent selected from hydroxyl, $-\text{NR}^{45}\text{R}^{46}$, $-\text{COOR}^{47}$, $-\text{CONR}^{48}\text{R}^{49}$, $-\text{SO}_2\text{NR}^{50}\text{R}^{51}$, $-\text{NR}^{52}\text{SO}_2\text{R}^{53}$, $-\text{NR}^{66}\text{C(O)R}^{67}$, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio and C_1 - C_6 alkoxy carbonyl;

Z, Z' and Z'' independently represent a bond, O, S, SO, SO_2 , $>\text{NR}^{78}$, C_1 - C_6 alkylene, or a group $-\text{O}(\text{CH}_2)_{1-6}-$, $-\text{NR}^{79}(\text{CH}_2)_{1-6}-$ or $-\text{S(O)}_p(\text{CH}_2)_{1-6}-$ wherein p is 0, 1 or 2;

R^{68} , R^{69} and R^{80} independently represent tetrazolyl or a 5- to 6- membered heterocyclic ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which heterocyclic ring is substituted by at least one substituent selected from hydroxyl, =O, and =S, and which heterocyclic ring may further be optionally substituted by at least one substituent selected from halogen, nitro, cyano, $-\text{SO}_2\text{C}_{1-6}$ alkyl, C_{1-6}

alkoxycarbonyl, and a C₁₋₆ alkyl group which C₁₋₆ alkyl group can be optionally substituted by at least one substituent selected from halogen and hydroxyl;

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represent hydrogen or C₁₋₆ alkyl optionally substituted by at least one substituent selected from hydroxyl,

5 halogen and C₁₋₆ alkoxy;

R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³², R³³, R³⁴ and R³⁵ each independently represent hydrogen or C₁₋₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁₋₆ alkoxy;

10 R³⁶, R³⁷, R³⁸, R³⁹, R⁴⁰, R⁴¹, R⁴², R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹, R⁵⁰, R⁵¹, R⁵² and R⁵³ each independently represent hydrogen or C₁₋₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁₋₆ alkoxy;

R⁵⁴, R⁵⁵, R⁵⁶, R⁵⁷, R⁵⁸, R⁵⁹, R⁶⁰, R⁶¹, R⁶², R⁶³, R⁶⁴, R⁶⁵, R⁶⁶ and R⁶⁷ each independently represent hydrogen or C₁₋₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁₋₆ alkoxy; and

15 R⁷⁰, R⁷¹, R⁷², R⁷³, R⁷⁴, R⁷⁵, R⁷⁶, R⁷⁷, R⁷⁸ and R⁷⁹ each independently represent hydrogen or C₁₋₆ alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C₁₋₆ alkoxy;

with the provisos that:

- (a) when X represents NHC(O), p is 0, q is 0, n is 1 and R³, R⁵ and R⁶ each
20 independently represent hydrogen, then R² is other than a 2-carboxy-phenyl group; and
- (b) when X represents NHC(O), p is 0, q is 0, n is 2, R³ represents hydrogen and each R⁵ and R⁶ independently represents hydrogen, then R² is other than a 3,4-diamino-phenyl group or a 5-methyl-2-furanyl group; and
- 25 (c) when X represents C(O)NH, p is 0, q is 0, n is 2, R³ represents hydrogen and each R⁵ and R⁶ independently represents hydrogen, then R² is other than an unsubstituted phenyl group, an unsubstituted 1H-indol-3-yl group, or a 2-methyl-1H-indol-3-yl group.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl substituent or an alkyl or alkenyl moiety in a substituent group may be linear or branched. Examples of alkyl groups/moieties containing up to 7 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl and n-heptyl. A

- 5 hydroxyalkyl or hydroxyalkoxy substituent may contain one or more hydroxyl groups but preferably contains one or two hydroxyl groups. When R^7 and R^8 (or R^9 and R^{10}) represent a 4- to 7-membered saturated heterocycle, it should be understood that the heterocycle will contain no more than three ring heteroatoms: the nitrogen ring atom to which R^7 and R^8 (or R^9 and R^{10}) are attached and optionally one or two further ring
- 10 heteroatoms independently selected from nitrogen, oxygen and sulphur. When either of R^7 and R^8 represents a saturated or unsaturated 3- to 10-membered heterocyclic ring system, it should be understood that the ring system may have alicyclic or aromatic properties. Furthermore, an unsaturated ring system will be partially or fully unsaturated. The same comments apply to the saturated or unsaturated 3- to 10-membered ring system in the
- 15 definition of R^9/R^{10} . Similarly, the unsaturated 4- to 10-membered ring system in the definition of R^2 may be fully or partially unsaturated.

- Each R^1 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), or C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
- 20 tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

- 25 In an embodiment of the invention, p is 0 or p is 1 and R^1 represents halogen, in particular chlorine.

In an embodiment of the invention, n is 1, 2, 3 or 4. In another embodiment, n is 1, 2 or 3. In yet another embodiment, n is 2.

Within each grouping, CR^5R^6 , R^5 and R^6 each independently represent hydrogen, halogen (e.g. chlorine, fluorine, bromine or iodine), phenyl or C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), or R^5 and R^6 together with the carbon atom to which they are both attached form a C_3 - C_8 ,
 5 preferably C_5 - C_6 , cycloalkyl ring (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl).

In an embodiment of the invention, R^5 and R^6 each independently represent hydrogen, halogen, or C_1 - C_6 alkyl, or R^5 and R^6 together with the carbon atom to which they are
 10 both attached form a C_3 - C_8 cycloalkyl ring.

In another embodiment of the invention, R^5 and R^6 each independently represent hydrogen or C_1 - C_4 alkyl, in particular methyl.

15 R^2 represents an unsaturated 4- to 10-membered, preferably 4- to 9-membered, more preferably 4- to 6-membered, ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one
 20 substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), $-COOR^{13}$, hydroxyl, $-NR^{14}R^{15}$, $-CONR^{16}R^{17}$, $-SO_2NR^{18}R^{19}$, $-NR^{20}SO_2R^{21}$, C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), C_1 - C_6 , preferably C_1 - C_4 , alkylcarbonyl (e.g. methylcarbonyl or ethylcarbonyl), C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C_1 - C_6 ,
 25 preferably C_1 - C_4 , alkylcarbonyloxy (e.g. methylcarbonyloxy or ethylcarbonyloxy), C_1 - C_6 , preferably C_1 - C_4 , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C_1 - C_6 , preferably C_1 - C_4 , hydroxyalkyl (e.g. $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$ or $-CH(OH)CH_3$) and $-S(O)_mC_1$ - C_6 , preferably C_1 - C_4 , alkyl where m is 0, 1 or 2 (e.g. methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, methylsulphonyl or ethylsulphonyl)

In R^2 , the unsaturated 4- to 10-membered ring system may be monocyclic or polycyclic (e.g. bicyclic) and may be partially or fully unsaturated. Examples of ring systems that may be used include one or more (in any combination) of cyclopentenyl, cyclohexenyl, phenyl, pyrazolyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, 5 furyl, thiazolyl, indolyl, imidazolyl, benzimidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl or pyrazinyl. Preferred ring systems include phenyl, furyl, thienyl and pyridinyl.

In an embodiment of the invention, R^2 represents an unsaturated 4-, 5- or 6-membered ring 10 optionally comprising one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen, $-COOR^{13}$, hydroxyl, $-NR^{14}R^{15}$, $-CONR^{16}R^{17}$, $-SO_2NR^{18}R^{19}$, $-NR^{20}SO_2R^{21}$, C_1 - C_4 alkyl, C_1 - C_4 alkylcarbonyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylcarbonyloxy, C_1 - C_4 alkoxycarbonyl, C_1 - C_4 hydroxyalkyl and 15 $-S(O)_mC_1$ - C_4 alkyl where m is 0, 1 or 2.

In another embodiment of the invention, R^2 represents an unsaturated 6-membered ring optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from halogen (particularly chlorine) and C_1 - C_4 alkoxy 20 (particularly methoxy).

Each R^4 independently represents halogen (e.g. chlorine, fluorine, bromine or iodine), or C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, 25 two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

In an embodiment of the invention, q is 0 or q is 1 and R^4 represents halogen, in particular 30 chlorine.

In an embodiment of the invention, R^3 represents a group $-R^7$, $-OR^7$, $-SR^7$ or $-NR^7R^8$.

In another embodiment of the invention, R^3 represents hydrogen or a group $-R^7$ or $-NR^7R^8$.

R^7 and R^8 each independently represent hydrogen, C_1 - C_{10} , preferably C_1 - C_6 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl or n-decyl), C_3 - C_8 , preferably C_5 - C_6 , cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) or a saturated or unsaturated 3- to 10-membered heterocyclic ring system comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the alkyl, cycloalkyl and heterocyclic ring system each being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C_1 - C_6 , preferably C_1 - C_4 , alkylthio (e.g. methylthio, ethylthio, n-propylthio or n-butylthio), C_1 - C_6 , preferably C_1 - C_4 , hydroxyalkyl (e.g. $-\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$ or $-\text{CH}(\text{OH})\text{CH}_3$), C_1 - C_6 , preferably C_1 - C_4 , hydroxyalkoxy (e.g. $-\text{O}-\text{CH}_2\text{CH}_2\text{OH}$ or $-\text{O}-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$), C_1 - C_6 , preferably C_1 - C_4 , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C_3 - C_8 , preferably C_5 - C_6 , cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), $-\text{NR}^9\text{R}^{10}$, $-\text{COOR}^{22}$, $-\text{CONR}^{23}\text{R}^{24}$, $-\text{SO}_2\text{NR}^{25}\text{R}^{26}$, $-\text{NR}^{27}\text{SO}_2\text{R}^{28}$ and ZR^{68} .

Examples of saturated or unsaturated 3- to 10-membered heterocyclic ring systems R^7 and R^8 , which may be monocyclic or polycyclic (e.g. bicyclic), include one or more (in any combination) of pyrrolidinyl, piperidinyl, pyrazolyl, homopiperidinyl, thiazolidinyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, indolyl, quinolinyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.

In an embodiment of the invention, R^7 and R^8 each independently represent hydrogen or C_1 - C_{10} , preferably C_1 - C_6 , alkyl optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from halogen, hydroxyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 hydroxyalkyl, C_1 - C_4 hydroxyalkoxy, C_1 - C_4 alkoxycarbonyl,
 5 C_5 - C_6 cycloalkyl, $-NR^9R^{10}$, $-COOR^{22}$, $-CONR^{23}R^{24}$, $-SO_2NR^{25}R^{26}$ and $-NR^{27}SO_2R^{28}$.

In a further embodiment, R^7 and R^8 each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted by $-NR^9R^{10}$.

10

Alternatively, when R^3 represents $-NR^7R^8$, R^7 and R^8 may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur and that optionally further comprises a bridging group (e.g.
 15 pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl or diazabicyclo[2.2.1]hept-2-yl), the heterocyclic ring being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C_1 - C_6 , preferably
 20 C_1 - C_4 , alkylthio (e.g. methylthio, ethylthio, n-propylthio or n-butylthio), C_1 - C_6 , preferably C_1 - C_4 , hydroxyalkyl (e.g. $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2CH_2CH_2OH$ or $-CH(OH)CH_3$), C_1 - C_6 , preferably C_1 - C_4 , hydroxyalkoxy (e.g. $-O-CH_2CH_2OH$ or $-O-CH_2CH_2CH_2OH$), C_1 - C_6 , preferably C_1 - C_4 , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C_3 - C_8 , preferably C_5 - C_6 , cycloalkyl (e.g. cyclopropyl, cyclobutyl,
 25 cyclopentyl or cyclohexyl), $-NR^{11}R^{12}$, $-COOR^{29}$, $-CONR^{30}R^{31}$, $-SO_2NR^{32}R^{33}$, $-NR^{34}SO_2R^{35}$, $Z'R^{69}$, $(CH_2)_{1-6}NR^{70}R^{71}$, SO_2R^{72} , $NR^{73}CONR^{74}SO_2R^{75}$ or $M(CH_2)_1$ - $6COOR^{76}$ wherein M represents a bond, O, S, SO, SO_2 , and a group $>NR^{77}$.

In an embodiment of the invention, R^7 and R^8 together with the nitrogen atom to which
 30 they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally

further comprises a ring nitrogen atom, the heterocyclic ring being optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from halogen, hydroxyl, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₁-C₄ hydroxyalkyl, C₁-C₄ hydroxyalkoxy, C₁-C₄ alkoxycarbonyl, C₅-C₆ cycloalkyl, -NR¹¹R¹², -COOR²⁹,
 5 -CONR³⁰R³¹, -SO₂NR³²R³³ and -NR³⁴SO₂R³⁵.

In another embodiment, R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen atom, the heterocyclic ring being optionally substituted by
 10 -NR¹¹R¹².

R⁹ and R¹⁰ each independently represent hydrogen or a C₁-C₆, preferably C₁-C₄, alkylcarbonyl (e.g. methylcarbonyl or ethylcarbonyl), C₂-C₇ alkenyl (e.g. ethenyl, prop-1-enyl, prop-2-enyl, but-1-enyl, pent-1-enyl, hex-1-enyl, hept-1-enyl or
 15 2-methyl-pent-2-enyl) or C₁-C₇, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl and n-heptyl) group, each group being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from hydroxyl, -NR³⁶R³⁷, -COOR³⁸,
 -CONR³⁹R⁴⁰, -SO₂NR⁴¹R⁴², -NR⁴³SO₂R⁴⁴, C₁-C₆, preferably C₁-C₄, alkoxy (e.g.
 20 methoxy, ethoxy, n-propoxy or n-butoxy), C₁-C₆, preferably C₁-C₄, alkylthio (e.g. methylthio, ethylthio, n-propylthio or n-butylthio), C₁-C₆, preferably C₁-C₄, alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl) and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from
 25 nitrogen, oxygen and sulphur, the ring system in turn being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine), hydroxyl, oxo, carboxyl, cyano, C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) and C₁-C₆, preferably C₁-C₄, hydroxyalkyl (e.g.
 30 -CH₂OH, -CH₂CH₂OH, -CH₂CH₂CH₂OH or -CH(OH)CH₃).

Examples of saturated or unsaturated 3- to 10-membered ring systems R^9 and R^{10} , which may be monocyclic or polycyclic (e.g. bicyclic), include one or more (in any combination) of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, pyrazolyl, thiazolidinyl, indanyl, thienyl, isoxazolyl, thiadiazolyl, pyrrolyl, furyl, thiazolyl, indolyl, imidazolyl, benzimidazolyl, triazolyl, tetrazolyl and pyridinyl.

- Alternatively, R^9 and R^{10} may together together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur (e.g. pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl), the heterocyclic ring being optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from $-OR^{54}$, $-NR^{55}R^{56}$, $-(CH_2)_t-NR^{57}R^{58}$ where t is 1, 2, 3, 4, 5 or 6, $-COOR^{59}$, $-CONR^{60}R^{61}$, $-SO_2NR^{62}R^{63}$, $-NR^{64}SO_2R^{65}$, C_1-C_6 , preferably C_1-C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C_1-C_6 , preferably C_1-C_4 , alkylthio (e.g. methylthio, ethylthio, n-propylthio or n-butylthio), C_1-C_6 , preferably C_1-C_4 , alkoxycarbonyl (e.g. methoxycarbonyl or ethoxycarbonyl) and $Z''R^{80}$.

20

In an embodiment of the invention, R^9 and R^{10} each independently represent hydrogen or C_1-C_4 alkyl optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from hydroxyl, $-NR^{36}R^{37}$, $-COOR^{38}$, $-CONR^{39}R^{40}$, $-SO_2NR^{41}R^{42}$, $-NR^{43}SO_2R^{44}$, C_1-C_4 alkoxy, C_1-C_4 alkylthio, C_1-C_4 alkoxycarbonyl and a saturated or unsaturated 5- to 10-membered ring system which may comprise at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms independently) selected from nitrogen, oxygen and sulphur, the ring system in turn being optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from halogen, hydroxyl, oxo, carboxyl, cyano, C_1-C_4 alkyl and C_1-C_4 hydroxyalkyl.

30

In another embodiment, R^9 and R^{10} each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from hydroxyl (e.g. methyl, ethyl, $-CH_2CH_2OH$ or $-CH_2CH_2CH_2OH$).

5

R^{11} and R^{12} each independently represent hydrogen or a C_1 - C_6 , preferably C_1 - C_4 , alkylcarbonyl (e.g. methylcarbonyl or ethylcarbonyl), C_1 - C_6 , preferably C_1 - C_4 , alkoxy carbonyl (e.g. methoxycarbonyl or ethoxycarbonyl), C_2 - C_7 alkenyl (e.g. ethenyl, prop-1-enyl, prop-2-enyl, but-1-enyl, pent-1-enyl, hex-1-enyl, hept-1-enyl or 2-methyl-pent-2-enyl) or C_1 - C_7 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl and n-heptyl) group, each group being optionally substituted with at least one substituent (e.g. one, two, three or four substituents independently) selected from hydroxyl, $-NR^{45}R^{46}$, $-COOR^{47}$, $-CONR^{48}R^{49}$, $-SO_2NR^{50}R^{51}$, $-NR^{52}SO_2R^{53}$, $-NR^{66}C(O)R^{67}$, C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy), C_1 - C_6 , preferably C_1 - C_4 , alkylthio (e.g. methylthio, ethylthio, n-propylthio or n-butylthio) and C_1 - C_6 , preferably C_1 - C_4 , alkoxy carbonyl (e.g. methoxycarbonyl or ethoxycarbonyl).

In an embodiment of the invention, R^{11} and R^{12} each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from hydroxyl, $-NR^{45}R^{46}$, $-COOR^{47}$, $-CONR^{48}R^{49}$, $-SO_2NR^{50}R^{51}$, $-NR^{52}SO_2R^{53}$, $-NR^{66}C(O)R^{67}$, C_1 - C_4 alkylamino, di- C_1 - C_4 alkylamino, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio and C_1 - C_4 alkoxy carbonyl.

In another embodiment, R^{11} and R^{12} each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted with at least one substituent (e.g. one or two substituents independently) selected from hydroxyl (e.g. methyl, ethyl, $-CH_2CH_2OH$ or $-CH_2CH_2CH_2OH$).

Z, Z' and Z'' independently represent a bond, O, S, SO, SO₂, >NR⁷⁸, C₁₋₆ alkylene, or a group -O(CH₂)₁₋₆-, -NR⁷⁹(CH₂)₁₋₆- or -S(O)_p(CH₂)₁₋₆- wherein p is 0, 1 or 2.

In an embodiment of the invention Z, Z' and Z'' independently represent a bond, O,
 5 >NR⁷⁸ or a group -O(CH₂)₁₋₆-, preferably a bond.

R⁶⁸, R⁶⁹ and R⁸⁰ independently represent tetrazolyl or a 5- to 6-membered, preferably 5-membered, heterocyclic ring comprising from 1 to 4, preferably 1 to 3 and more preferably 2 to 3, heteroatoms selected from nitrogen, oxygen and sulphur, which heterocyclic ring is
 10 substituted by at least one substituent (e.g. one two or three substituents independently) selected from hydroxyl, =O, and =S, and which heterocyclic ring may further be optionally substituted by at least one substituent selected from halogen (e.g. chlorine, fluorine, bromine or iodine), nitro, cyano, -SO₂C₁₋₆ alkyl, C₁₋₆ alkoxy carbonyl, and a C₁₋₆, preferably C₁₋₄, alkyl group which alkyl group can be optionally substituted by at least one
 15 substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. chlorine, fluorine, bromine or iodine) and hydroxyl.

R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰ and R²¹ each independently represent hydrogen or C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C₁-C₆, preferably C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

25 R²², R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰, R³¹, R³², R³³, R³⁴ and R³⁵ each independently represent hydrogen or C₁-C₆, preferably C₁-C₄, alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C₁-C₆, preferably
 30 C₁-C₄, alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

$R^{36}, R^{37}, R^{38}, R^{39}, R^{40}, R^{41}, R^{42}, R^{43}, R^{44}, R^{45}, R^{46}, R^{47}, R^{48}, R^{49}, R^{50}, R^{51}, R^{52}$ and R^{53} each independently represent hydrogen or C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

$R^{54}, R^{55}, R^{56}, R^{57}, R^{58}, R^{59}, R^{60}, R^{61}, R^{62}, R^{63}, R^{64}, R^{65}, R^{66}$ and R^{67} each independently represent hydrogen or C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

$R^{70}, R^{71}, R^{72}, R^{73}, R^{74}, R^{75}, R^{76}, R^{77}, R^{78}$ and R^{79} each independently represent hydrogen or C_1 - C_6 , preferably C_1 - C_4 , alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted by at least one substituent (e.g. one, two or three substituents independently) selected from hydroxyl, halogen (e.g. chlorine, fluorine, bromine or iodine) and C_1 - C_6 , preferably C_1 - C_4 , alkoxy (e.g. methoxy, ethoxy, n-propoxy or n-butoxy).

In an embodiment of the invention:

p is 0 or 1;

R^1 represents halogen;

X is $C(O)NH$ or $NHC(O)$;

n is 1, 2, 3, 4 or 5;

within each grouping, CR^5R^6 , R^5 and R^6 each independently represent hydrogen or C_1 - C_6 alkyl;

R^2 represents an unsaturated 4- to 6-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen and C_1 - C_6 alkoxy;

5 R^3 represents hydrogen or a group $-R^7$ or $-NR^7R^8$;

q is 0;

R^7 and R^8 each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted by $-NR^9R^{10}$, or

alternatively, R^7 and R^8 together with the nitrogen atom to which they are attached
10 form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen atom, the heterocyclic ring being optionally substituted by $-NR^{11}R^{12}$ or carboxyl;

R^9 and R^{10} each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted with at least one substituent selected from hydroxyl; and

15 R^{11} and R^{12} each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted with at least one substituent selected from hydroxyl.

In a further embodiment of the invention:

p is 0 or 1;

20 R^1 represents chlorine;

X is $C(O)NH$ or $NHC(O)$;

n is 2;

within each grouping, CR^5R^6 , R^5 and R^6 each independently represent hydrogen or methyl;

25 R^2 represents phenyl optionally substituted with one or two substituents selected from chlorine and methoxy;

R^3 represents hydrogen or a group $-R^7$ or $-NR^7R^8$;

q is 0;

30 R^7 and R^8 each independently represent hydrogen or C_1 - C_4 alkyl optionally substituted by $-NR^9R^{10}$, or

alternatively, R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen atom, the heterocyclic ring being optionally substituted by -NR¹¹R¹² or carboxyl;

5 R⁹ and R¹⁰ each independently represent hydrogen or C₁-C₄ alkyl optionally substituted with at least one substituent selected from hydroxyl; and

R¹¹ and R¹² each independently represent hydrogen or C₁-C₄ alkyl optionally substituted with at least one substituent selected from hydroxyl.

10 In an embodiment of the invention the compound of formula (I) is selected from

6-Chloro-2-methyl-*N*-[(2*R*)-2-phenylpropyl]-5-quinolinecarboxamide,

6-Chloro-2-methyl-*N*-[(2*S*)-2-phenylpropyl]-5-quinolinecarboxamide,

(β*R*)-*N*-[6-Chloro-2-[methyl[3-(methylamino)propyl]amino]-5-quinolinyl]-β-methyl-benzenepropanamide,

15 (β*R*)-*N*-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-β-methyl-benzenepropanamide,

6-Chloro-2-methyl-*N*-(2-phenylethyl)-5-quinolinecarboxamide,

(β*R*)-*N*-[6-Chloro-2-[3-(ethylamino)propyl]-5-quinolinyl]-β-methyl-benzenepropanamide,

(β*R*)-*N*-[6-Chloro-2-[3-[(3-hydroxypropyl)amino]propyl]-5-quinolinyl]-β-methyl-

20 benzenepropanamide,

3,4-Dichloro-α-methyl-*N*-5-quinolinyl-benzenepropanamide,

(β*R*)-*N*-[6-Chloro-2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]-β-methyl-benzenepropanamide,

2-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,

25 2,4-Dichloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,

4-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,

(β*R*)-*N*-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]-β-methyl-benzenepropanamide,

N-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-2-methoxy-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(3-hydroxypropyl)amino]-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide,

5 *N*-[6-Chloro-2-(1-piperazinyl)-5-quinoliny]-benzenepropanamide,

N-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinoliny]-2-chloro-benzenepropanamide,

2-Chloro-*N*-[6-chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinoliny]-benzenepropanamide,

10 1-[6-Chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinoliny]-4-piperidinecarboxylic acid,

2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide,

6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinecarboxamide,

15 1-[6-Chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

20 1-[6-Chloro-5-[[[2,2-diphenylethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-phenylethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

25 1-[6-Chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[(2*S*)-2-phenylpropyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidinyl]-5-quinolinecarboxamide, and

1-[6-Chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

5 and all their pharmaceutically acceptable salts and solvates.

Suitable pharmaceutically acceptable salts of compounds of formula (I) include acid addition salts such as methanesulphonate, fumarate, hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulphuric acid. In another aspect, where the
 10 compound is sufficiently acidic, suitable salts include base salts such as an alkali metal salt for example sodium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, *N*-methylpiperidine, *N*-ethylpiperidine, procaine, dibenzylamine, *N,N*-dibenzylethylamine or amino acids for example lysine. There may be more than one cation or anion depending on the number of
 15 charged functions and the valency of the cations or anions. A preferred pharmaceutically acceptable salt is a hydrochloride salt.

Examples of compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof, include:-

20 6-Chloro-2-methyl-*N*-[(2*R*)-2-phenylpropyl]-5-quinolinecarboxamide, hydrochloride,
 6-Chloro-2-methyl-*N*-[(2*S*)-2-phenylpropyl]-5-quinolinecarboxamide, hydrochloride,
 (β *R*)-*N*-[6-Chloro-2-[methyl[3-(methylamino)propyl]amino]-5-quinolinyl]- β -methyl-
 benzenepropanamide ditrifluoroacetate,
 (β *R*)-*N*-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]- β -methyl-benzenepropanamide,
 25 6-Chloro-2-methyl-*N*-(2-phenylethyl)-5-quinolinecarboxamide,
 (β *R*)-*N*-[6-Chloro-2-[3-(ethylamino)propyl]-5-quinolinyl]- β -methyl-
 benzenepropanamide dihydrochloride,
 (β *R*)-*N*-[6-Chloro-2-[3-[(3-hydroxypropyl)amino]propyl]-5-quinolinyl]- β -methyl-
 benzenepropanamide,
 30 3,4-Dichloro- α -methyl-*N*-5-quinolinyl-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]- β -methyl-benzenepropanamide dihydrochloride,

2-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide dihydrochloride,

5 2,4-Dichloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide dihydrochloride,

4-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide dihydrochloride,

(βR)-*N*-[2-[(3*S*)-3-amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]- β -methyl-
10 benzenepropanamide,

N-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-2-methoxy-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(3-hydroxypropyl)amino]-1-pyrrolidinyl]-5-quinolinyl]- β -methyl-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-
15 quinolinyl]- β -methyl-benzenepropanamide, dihydrochloride,

N-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,

N-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]-2-chloro-benzenepropanamide,

2-Chloro-*N*-[6-chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-
20 quinolinyl]-benzenepropanamide,

1-[6-Chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinolinyl]-4-piperidinecarboxylic acid, potassium salt,

2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide,

25 6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinecarboxamide,

1-[6-Chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-
30 piperidinecarboxylic acid,

1-[6-Chloro-5-[[2-(2-diphenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid, acetate,

1-[6-Chloro-5-[[2-(phenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,

5 1-[6-Chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,

10 1-[6-Chloro-5-[[[2-(2S)-2-phenylpropyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,

6-Chloro-N-[2-(2-chlorophenyl)ethyl]-2-[4-(1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)-1-piperidinyl]-5-quinolinecarboxamide, and

1-[6-Chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid.

15

Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. Tautomers and mixtures thereof also form an aspect of the present invention.

20

The present invention also extends to suitable prodrugs of compounds of formula (I), i.e. compounds which are hydrolysed *in vivo* to form compounds of formula (I). Thus for example where compounds of formula (I) include a carboxy group, these may be in the form of pharmaceutically acceptable esters or amides. Suitable pharmaceutically

25 acceptable esters of formula (I) for carboxy groups include C₁₋₆alkyl esters, for example methyl or ethyl; C₁₋₆alkoxymethyl esters, for example methoxymethyl;

C₁₋₆alkanoyloxymethyl esters, for example pivaloyloxymethyl; phthalidyl esters;

C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters, for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-ylmethyl esters, for example 5-methyl-1,3-dioxolan-2-ylmethyl;

30 C₁₋₆alkoxycarbonyloxyethyl esters, for example 1-methoxycarbonyloxyethyl;

aminocarbonylmethyl esters and mono- or di- N-(C₁₋₆alkyl) versions thereof, for example N,N-dimethylaminocarbonylmethyl esters and N-ethylaminocarbonylmethyl esters; and may be formed at any carboxy group in the compounds of this invention. An *in vivo* cleavable ester of a compound of the invention containing a hydroxy group is, for example,


5 a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent hydroxy group. Suitable pharmaceutically acceptable esters for hydroxy include C₁₋₆alkanoyl esters, for example acetyl esters; and benzoyl esters wherein the phenyl group may be substituted with aminomethyl or N- substituted mono- or di-C₁₋₆alkyl aminomethyl, for example 4-aminomethylbenzoyl esters and

10 4-N,N-dimethylaminomethylbenzoyl esters. Pharmaceutically acceptable amides are similarly *in-vivo* hydrolysable to yield the parent acid, and include C₁₋₆alkylamides such as acetamide.

The present invention further provides a process for the preparation of a compound of

15 formula (I) as defined above, or a pharmaceutically acceptable salt or solvate thereof, which comprises

(a) reacting a compound of formula




20 wherein L¹ represents a leaving group (e.g. hydroxyl or halogen) and p, q, R¹, R³ and R⁴ are as defined in formula (I), with a compound of formula



wherein n, R², R⁵ and R⁶ are as defined in formula (I); or

25 (b) reacting a compound of formula




wherein p , q , R^1 , R^3 and R^4 are as defined in formula (I), with a compound of formula

$$L^2C(O) - (CR^5R^6)_n - R^2 \quad (V)$$


wherein L^2 represents a leaving group (e.g. hydroxyl or halogen) and n , R^2 , R^5 and R^6 are
 5 as defined in formula (I); or

(c) when R^3 represents a group $-NR^7R^8$, reacting a compound of formula



wherein L^3 is a leaving group (e.g. chloride, bromide, fluoride, iodide,
 10 paratoluenesulphonate or methanesulphonate) and n , p , q , X , R^1 , R^2 , R^4 , R^5 and R^6 are as defined in formula (I), with a compound of formula (VII), $H-NR^7R^8$, wherein R^7 and R^8 are as defined in formula (I); or


(d) when R^3 represents a group R^7 where R^7 is an optionally substituted C_3 - C_{10} alkyl
 15 group, reacting a compound of formula (VI) as defined in (c) above with a compound of formula



wherein R^{7a} represents a C_1 - C_8 alkyl group optionally substituted as defined for R^7 in
 formula (I), optionally followed by a hydrogenation reaction; or


20

(e) when R^3 represents a group R^7 where R^7 is $-(CH_2)_2NR^9R^{10}$, reacting a compound
 of formula (VI) as defined in (c) above with a compound of formula




wherein L^4 is a leaving group (eg. trialkyltin, dialkylboron or zinc), followed by reaction with a compound of formula (XI), HNR^9R^{10} , wherein R^9 and R^{10} are as defined in formula (I); or

- 5 (f) when R^3 represents a group R^7 where R^7 is $-CH_2NR^9R^{10}$, reacting a compound of formula (VI) as defined in (c) above with a compound of formula (X) as defined in (e) above, followed by an oxidation reaction and then by reaction with a compound of formula (XI) as defined in (e) above under reductive amination conditions; or
- 10 (g) when R^3 represents a group R^7ZR^{68} or NR^7R^8 wherein R^7 and/or R^8 are substituted by a group $Z'R^{69}$ or R^7 and R^8 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring substituted by a group $Z'R^{69}$, and R^{68} or R^{69} is tetrazolyl, reacting a group of formula (XII) or (XIII)




with a compound of formula GN_3 , wherein G is sodium, a trialkylsilyl, an alkyltin or ammonium, to yield a group of formula (I) wherein R^7 , R^8 , Z, Z' are as defined in formula (I); or

- 20 (h) when R^3 represents a group R^7ZR^{68} or NR^7R^8 wherein R^7 and/or R^8 are substituted by a group $Z'R^{69}$ or R^7 and R^8 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring substituted by a group $Z'R^{69}$, and R^{68} or R^{69} is group of formula




reacting a compound of formula XII or XIII wherein XII or XIII are as defined in (g) above with hydroxylamine, followed by treatment with 1,1'-thiocarbonyldiimidazole and subsequent treatment with silica gives a group of formula (XIV) wherein J is S, alternatively reacting a compound of formula XII or XIII wherein XIII or XIII are as defined in (g) above with hydroxylamine, followed by treatment with a suitable chloroformate gives a group of formula (XIV) wherein J is O; or

(i) when R^3 represents a group R^7ZR^{68} or NR^7R^8 wherein R^7 and/or R^8 are substituted by a group $Z'R^{69}$ or R^7 and R^8 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring substituted by a group $Z'R^{69}$, and R^{68} or R^{69} is



reacting a compound of formula XVI or XVII



with a source of phosgene followed by treatment with formyl hydrazine and subsequent treatment with base;

and optionally after (a), (b), (c), (d), (e), (f), (g), (h) or (i) carrying out one or more of the following:

- converting the compound obtained to a further compound of the invention
- forming a pharmaceutically acceptable salt or solvate of the compound.

In processes (a) and (b) the coupling reaction is conveniently carried out in an organic solvent such as acetone, dichloromethane, *N,N*-dimethylformamide or 1-methyl-2-

pyrrolidinone. If L^1 or L^2 represent a hydroxyl group, it may be necessary or desirable to use a coupling agent such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBroP). If L^1 or L^2 are chloride, such compounds may be conveniently prepared by

treatment of the corresponding carboxylic acid derivative under standard conditions (such as thionyl chloride in dichloromethane with additional *N,N*-dimethylformamide) and used in a solvent such as acetone or dichloromethane with a suitable base such as potassium carbonate or triethylamine.

5

In process (c) the reaction may be performed in an organic solvent such as acetonitrile, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone, and in the presence of a suitable base such as sodium hydride, triethylamine or potassium carbonate.

- 10 In process (d), if the compound of formula (VI) is reacted with a compound of formula (VIII), then the reaction is conveniently carried out in an organic solvent such as acetonitrile, e.g. at ambient temperature (20°C), in the presence of catalytic bistriphenylphosphine dichloride palladium(0), copper (I) iodide and a base (e.g. triethylamine). The subsequent hydrogenation reaction may use hydrogen gas with a
15 catalyst such as 5% rhodium on carbon in a solvent, for example, ethyl acetate or ethanol, and at a pressure of 3 bar.

- Alternatively, if the compound of formula (VI) is reacted with a compound of formula (IX), then it is preferred if the compound of formula (IX) is pre-treated by reaction with a
20 hydroborating reagent (e.g. 9-borabicyclo[3.3.1]nonane or catecholborane) in an organic solvent such as diethyl ether or tetrahydrofuran at a temperature in the range from, e.g. 0°C to 80°C, in particular from 60°C to 70°C, for about 2 to 3 hours. The pre-treated compound is then reacted with the compound of formula (VI) in the presence of a suitable base (e.g. sodium hydroxide or tri-potassium orthophosphate) and a palladium catalyst
25 (e.g. dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane adduct, or *tetrakis*(triphenylphosphine)palladium(0)), typically at a temperature in the range from 25°C to 90°C, particularly from 60°C to 70°C, for about 2 to 24 hours.

- In process (e), the reaction with the vinyl compound of formula (X) may conveniently be
30 carried out in a solvent such as *N,N*-dimethylformamide and in the presence of catalytic

dichlorobis(triphenylphosphine) palladium, at elevated temperature, e.g. at about 70°C. The subsequent addition reaction with the compound of formula (XI) may be performed under acidic or basic conditions, for example, in acetic acid in a solvent such as methanol or *isopropanol* at elevated temperature, e.g. at about 100°C.

5

In process (f), the reaction of the vinyl compound of formula (X) may be performed by procedures analogous to those outlined in the previous paragraph on process (e). The subsequent oxidation reaction may be carried out under standard conditions, for example, by using ozone followed by treatment with dimethylsulfide or triphenylphosphine in a suitable solvent such as dichloromethane, or, by using osmium tetroxide and sodium periodate in a suitable solvent such as 1,4-dioxane and water. The reductive amination step may be conveniently carried out in the presence of a reducing agent such as sodium cyanoborohydride, triacetoxyborohydride or sodium borohydride, in a polar solvent such as methanol, ethanol or dichloromethane either alone or in combination with acetic acid.

10

In process (g), the compound of formula XII or XIII is treated with a compound of the formula GN_3 in a solvent (such as toluene, *N,N*-dimethylformamide or 1-methyl-2-pyrrolidinone) optionally in the presence of catalyst (such as dibutyltin oxide) at a temperature in the range from 70°C to 120°C.

15

In process (h), the compound of formula XII or XIII wherein XII or XIII are defined as in (g) and $\text{J} = \text{O}$, is treated with hydroxylamine in a suitable solvent (such as methanol or ethanol) at a temperature in the range from 20°C to 130°C. The resulting intermediate is treated with a suitable chloroformate (such as 2-ethylhexylchloroformate) in a suitable solvent (such as xylene) and heated at a temperature in the range from 70°C to 150°C to give the desired compounds of the formula (I). Alternatively, when $\text{J} = \text{S}$, treatment of the hydroxylamine adduct with 1,1'-thiocarbonyldiimidazole in a suitable solvent (such as tetrahydrofuran) and addition of silica yields the desired compounds of the formula (I).

20

25

In process (i), the compound of formula XVI or XVII is treated with phosgene or a phosgene equivalent (such as triphosgene) in a suitable solvent (such as dichloromethane) with a suitable base (such as triethylamine). The resulting compound is further treated with formyl hydrazine and the product subsequently treated with a base (such as potassium hydroxide) in a suitable solvent (such as methanol) at a temperature in the range from 50°C to 130°C to give the desired compounds of the formula (I).

Compounds of formulae (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII) and (XIII) are either commercially available, are known in the literature or may be prepared using known techniques.

Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures. For example, compounds of formula (I) in which R¹ represents a halogen atom may be converted to a corresponding compound of formula (I) in which R¹ represents a C₁-C₆ alkyl group by reaction with an alkyl Grignard reagent (e.g. methyl magnesium bromide) in the presence of a catalyst such as [1,3-bis(diphenylphosphino)propane]dichloronickel (II) in a solvent such as tetrahydrofuran.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at various stages, the addition and removal of one or more protecting groups.

The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1999).

The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt or solvate thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or *p*-toluenesulphonate, or an alkali metal salt such as a sodium or potassium salt. Other pharmaceutically acceptable salts, as well as prodrugs such as pharmaceutically acceptable esters and pharmaceutically acceptable amides may be prepared using conventional methods.

The compounds of the present invention are advantageous in that they possess pharmacological activity. They are therefore indicated as pharmaceuticals for use in the treatment of rheumatoid arthritis, osteoarthritis, psoriasis, allergic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), hyperresponsiveness of the airway, septic shock, glomerulonephritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, atherosclerosis, growth and metastases of malignant cells, myoblastic leukaemia, diabetes, Alzheimer's disease, meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke, varicose veins, sarcoidosis, rhinitis, acute and chronic pain, multiple sclerosis, myeloma, bone loss associated with malignancy and inflammatory and neurodegenerative diseases of the eye such as scleritis, episcleritis, uveitis, Sjogrens syndrome-keratoconjunctivitis, sclerokeratitis, optic neuritis, diabetic retinopathy, retinitis pigmentosa, and antimalarial-induced retinopathy. They are also advantageous in the treatment of infectious diseases, e.g. anthrax, in particular inflammatory disease caused or exacerbated by bacterial toxins.

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In another aspect, the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

5 The invention further provides a method of effecting immunosuppression (e.g. in the treatment of rheumatoid arthritis, osteoarthritis, irritable bowel disease, atherosclerosis or psoriasis) which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined to a patient.

10

The invention also provides a method of treating an obstructive airways disease (e.g. asthma or COPD) which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined to a patient.

15

For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of formula (I)/salt/solvate ("active ingredient") may be in the range from 0.001 mg/kg to 30 mg/kg.

20

The compounds of formula (I) and pharmaceutically acceptable salts or solvates thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt/solvate ("active ingredient") is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.10 to 70 %w, of active ingredient, and, from 1 to 99.95 %w, more preferably from 30 to 99.90 %w, of a pharmaceutically acceptable adjuvant, diluent or carrier, all percentages by weight being based on total composition.

30

Thus, the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

5

The pharmaceutical composition of the invention may be administered topically (e.g. to the lung and/or airways or to the skin) in the form of solutions, suspensions, heptafluoroalkane aerosols and dry powder formulations; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules, or by parenteral administration in the form of solutions or suspensions, or by subcutaneous administration or by rectal administration in the form of suppositories or transdermally.

10

The invention further relates to combination therapies for the treatment of any one of rheumatoid arthritis, osteoarthritis, osteoporosis, psoriasis, inflammatory bowel diseases, COPD, asthma, allergic rhinitis or cancer or the neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease or stroke.

15

For the treatment of rheumatoid arthritis, the compounds of the invention may be combined with "biological agents" such as TNF- α inhibitors such as anti-TNF monoclonal antibodies (such as Remicade, CDP-870 and Humira) and TNF receptor immunoglobulin molecules (such as Enbrel.reg.). IL-1 receptor antagonist (such as Anakinra) and IL-1 trap, IL-18 receptor, anti-IL-6 Ab, anti-CD20 Ab, anti-IL-15 Ab and CTLA4Ig.

20

Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin. The COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib and etoricoxib) and the cyclo-oxygenase inhibiting nitric oxide donors (CINOD's) and the "disease modifying agents" (DMARDs) such as methotrexate,

30

sulphasalazine, cyclosporine A, lefunomide; ciclesonide; hydroxychloroquine, d-penicillamine, auranofin or parenteral or oral gold.

The present invention still further relates to the combination of a compound of the
5 invention together with a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO)
inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist selected from the group
consisting of zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; N-(5-
substituted)-thiophene-2-alkylsulfonamides; 2,6-di-tert-butylphenol hydrazones;
methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; pyridinyl-
10 substituted 2n cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline
compounds such as L-746,530; indole and quinoline compounds such as MK-591, MK-
886, and BAY x 1005.

The present invention still further relates to the combination of a compound of the
15 invention together with a receptor antagonists for leukotrienes LTB₄, LTC₄, LTD₄, and
LTE₄ selected from the group consisting of the phenothiazin-3-ones such as L-651,392;
amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast;
benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast,
ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast
20 (CGP 45715A), and BAY x 7195.

The present invention still further relates to the combination of a compound of the
invention together with a PDE4 inhibitor including inhibitors of the isoform PDE4D.

25 The present invention still further relates to the combination of a compound of the
invention together with a antihistaminic H₁ receptor antagonists including cetirizine,
loratadine, desloratadine, fexofenadine, astemizole, azelastine, and chlorpheniramine.

The present invention still further relates to the combination of a compound of the
30 invention together with a gastroprotective H₂ receptor antagonist or the proton pump

inhibitors (such as omeprazole)

The present invention still further relates to the combination of a compound of the invention together with an α_1 - and α_2 -adrenoceptor agonist vasoconstrictor

- 5 sympathomimetic agent, including propylhexedrine, phenylephrine, phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, and ethylnorepinephrine hydrochloride.

- 10 The present invention still further relates to the combination of a compound of the invention together with anticholinergic agents including ipratropium bromide; tiotropium bromide; oxitropium bromide; pirenzepine; and telenzepine.

The present invention still further relates to the combination of a compound of the

- 15 invention together with a β_1 - to β_4 -adrenoceptor agonists including metaproterenol isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; or methylxanthanines including theophylline and aminophylline; sodium cromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

20

The present invention still further relates to the combination of a compound of the invention together with other modulators of chemokine receptor function such as CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C-C family); CXCR1, CXCR3, CXCR4 and CXCR5 (for the C-X-C

25 family) and CX₃CR1 for the C-X₃-C family.

The present invention still further relates to the combination of a compound of the invention together with an insulin-like growth factor type I (IGF-1) mimetic.

- 30 The present invention still further relates to the combination of compound of the invention

together with an inhaled glucocorticoid with reduced systemic side effects, including prednisone, prednisolone, flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, and mometasone furoate.

5 The present invention still further relates to the combination of a compound of the invention together with (a) tryptase inhibitors; (b) platelet activating factor (PAF) antagonists; (c) interleukin converting enzyme (ICE) inhibitors; (d) IMPDH inhibitors; (e) adhesion molecule inhibitors including VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors; (h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B₁ - and B₂ -
10 receptor antagonists; (j) anti-gout agents, e.g., colchicine; (k) xanthine oxidase inhibitors, e.g., allopurinol; (l) uricosuric agents, e.g., probenecid, sulfinpyrazone, and benzbromarone; (m) growth hormone secretagogues; (n) transforming growth factor (TGF β); (o) platelet-derived growth factor (PDGF); (p) fibroblast growth factor, e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophage colony stimulating factor
15 (GM-CSF); (r) capsaicin cream; (s) Tachykinin NK₁ and NK₃ receptor antagonists selected from the group consisting of NKP-608C; SB-233412 (talnetant); and D-4418; and (t) elastase inhibitors selected from the group consisting of UT-77 and ZD-0892 (u) induced nitric oxide synthase inhibitors (iNOS) or (v) chemoattractant receptor-homologous molecule expressed on TH2 cells, (CRTH2 antagonists).

20

The present invention still further relates to the combination of a compound of the invention together with an inhibitor of matrix metalloproteases (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1
25 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11).

The compounds of the invention can also be used in combination with existing therapeutic agents for the treatment of osteoarthritis. Suitable agents to be used in combination include standard non-steroidal anti-inflammatory agents (hereinafter NSAID's) such as
30 piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen,

ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, apazone, pyrazolones such as phenylbutazone, salicylates such as aspirin, induced nitric oxide synthase inhibitors (iNOS inhibitors), COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and etoricoxib, and the cyclo-oxygenase inhibiting nitric oxide
5 donors (CINOD's) analgesics (such as paracetamol and tramadol), cartilage sparing agents such as diacerein, doxycycline and glucosamine, and intra-articular therapies such as corticosteroids and hyaluronic acids such as hyalgan and synvisc.

The compounds of the invention can also be used in combination with existing therapeutic
10 agents for the treatment of inflammatory bowel diseases (Ulcerative colitis and Crohn's disease). Suitable agents to be used include sulphasalazine, 5-amino-salicylates, the thiopurines, azathioprine and 6-mercaptopurine and corticosteroids such as budesonide.

The compounds of the present invention may also be used in combination with anticancer
15 agents such as endostatin and angiostatin or cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and farnesyl transferase inhibitors, VegF inhibitors, COX-2 inhibitors and antimetabolites such as methotrexate, antineoplastic agents, especially antimitotic drugs including the vinca alkaloids such as vinblastine and vincristine.

20 The compounds of the invention may also be used in combination with antiviral agents such as Viracept, AZT, aciclovir and famciclovir, and antisepsis compounds such as Valant.

25 The compounds of the present invention may also be used in combination with cardiovascular agents such as calcium channel blockers, lipid lowering agents such as statins, fibrates, beta-blockers, Ace inhibitors, Angiotensin-2 receptor antagonists and platelet aggregation inhibitors.

30 The compounds of the present invention may also be used in combination with CNS agents


such as antidepressants (such as sertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors such as selegine and rasagiline, comP inhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors of neuronal nitric oxide synthase), and
5 anti Alzheimer's drugs such as donepezil, tacrine, COX-2 inhibitors, propentofylline or metryfonate.

The compounds of the present invention may also be used in combination with osteoporosis agents such as roloxifene, droloxifene, lasofoxifene or fosomax and
10 immunosuppressant agents such as FK-506, rapamycin, cyclosporine, azathioprine, and methotrexate.

The present invention will now be further explained by reference to the following illustrative examples. In the examples the NMR spectra were measured on a Varian Unity spectrometer at a proton frequency of either 300 or 400 MHz. The MS spectra were
15 measured on either an Agilent 1100 MSD G1946D spectrometer or a Hewlett Packard HP1100 MSD G1946A spectrometer. Preparative HPLC separations were performed using a Waters Symmetry® or Xterra® column using 0.1% aqueous trifluoroacetic acid: acetonitrile, 0.1% aqueous ammonia: acetonitrile or 0.1% ammonium acetate: acetonitrile
20 as the eluant. Microwave reactions were performed in a CEM Discover single mode microwave.

Example 1

6-Chloro-2-methyl-N-[(2R)-2-phenylpropyl]-5-quinolinecarboxamide, hydrochloride



(a) 6-Chloro-2-methyl-5-quinolinecarboxylic acid

Crotonaldehyde (1.50 mL) was added dropwise over a period of 1 hour to a mixture of 5-amino-2-chlorobenzoic acid (1.72 g), ferrous sulphate heptahydrate (0.77 g), sodium nitrobenzenesulphonate (1.23 g) and concentrated hydrochloric acid (11 mL) at 95°C. The reaction mixture was heated for a further 15 minutes then filtered whilst still hot. The resulting solid was extracted with boiling 2M aqueous hydrochloric acid solution (20 mL) and the extract combined with the filtrate. Ammonium acetate was then added to give a solution of pH 4, which was cooled in ice and the resultant precipitate collected by filtration and washed with water. The solid was dried in vacuo to give the sub-title compound (0.5 g) as a solid.

MS: APCI(+ve) 222/224 (M+1)


(b) 6-Chloro-2-methyl-N-[(2R)-2-phenylpropyl]-5-quinolinecarboxamide, hydrochloride

To a stirred solution of 6-chloro-2-methyl-5-quinolinecarboxylic acid (Example 1(a)) (250 mg) in dichloromethane (5 mL) at 0°C under nitrogen, was added *N,N*-dimethylformamide (1 drop) and oxalyl chloride (0.4 mL). The reaction mixture was stirred at room temperature for 1 hour, then evaporated to dryness and redissolved in dichloromethane (3 mL). This solution was cooled to 0°C and a mixture of (*R*)-2-phenyl-1-propylamine (152 mg) and triethylamine (1 mL) in dichloromethane (2 mL) was added dropwise. The reaction mixture was stirred at room temperature for 10 minutes then poured into saturated NaHCO₃ aq. (20 mL). The mixture was extracted with dichloromethane (3×20 mL) and the combined extracts were dried, filtered and evaporated. Purification (SiO₂, ethyl acetate:isohexane 1:1 as eluant) afforded the product which was converted to its hydrochloride salt by treatment with hydrochloric acid (4M in 1,4-dioxane) and recrystallised (ethanol / ethyl acetate) to give the title product (40 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.87 (1H, s), 8.15 (1H, d), 7.92 (1H, d), 7.75-7.66 (1H, m), 7.58 (1H, d), 7.40-7.24 (5H, m), 3.81-3.66 (1H, m), 3.52-3.39 (1H, m), 3.13-3.02 (1H, m), 2.80 (3H, s), 1.29 (3H, d).

MS: APCI(+ve) 339/341 (M+H⁺).

m.p. 190-192°C

Example 2**6-Chloro-2-methyl-N-[(2S)-2-phenylpropyl]-5-quinolinecarboxamide, hydrochloride**

- 5 Prepared according to the method of Example 1(b), using 6-chloro-2-methyl-5-quinolinecarboxylic acid (Example 1(a)) (250 mg) and (S)-2-phenyl-1-propylamine (152 mg). Purification (SiO₂, ethyl acetate:isohexane 1:1 as eluant) afforded the product which was converted to its hydrochloride salt by treatment with hydrochloric acid (4M in 1,4-dioxane) and recrystallised (ethanol / ethyl acetate) to give the title product (38 mg).

10

¹H NMR (400 MHz, d₆-DMSO) δ 8.89 (1H, t), 8.18 (1H, d), 7.94 (1H, d), 7.73 (1H, d), 7.60 (1H, d), 7.38-7.25 (5H, m), 3.80-3.68 (1H, m), 3.48-3.40 (1H, m), 3.14-3.04 (1H, m), 2.81 (3H, s), 1.29 (3H, d).


MS: APCI(+ve) 339/341 (M+H⁺).

15

m.p. 182-185°C

Example 3

(βR)-N-[6-Chloro-2-[methyl[3-(methylamino)propyl]amino]-5-quinolinyl]-β-methyl-benzenepropanamide, ditrifluoroacetate



(a) 2,6-Dichloroquinolin-5-amine

6-Chloro-5-nitroquinoline 1-oxide (4 g) was added to phosphorus oxychloride (15 mL) at 0°C. The solution was allowed to warm to room temperature and stirred for 12 hours. The excess phosphorus oxychloride was evaporated *in vacuo* and the residue dissolved in water (100 mL) / dichloromethane (100 mL). The layers were separated and the aqueous layer extracted with dichloromethane (2x50 mL). The combined extracts were dried over anhydrous magnesium sulfate, filtered and concentrated to give an oil. The residue was dissolved in ethanol/water (1:1, 80 mL), ammonium chloride (2.8 g) and iron (2.8 g) added. The mixture was stirred at 65°C for 4 hours, cooled to room temperature and filtered. The resulting solid was suspended in dimethylsulphoxide (50 mL), methanol (50 mL) and aqueous hydrochloric acid added (2M, 100 mL). The resulting solid was removed by filtration and then treated with ether (50 mL) and *isohexane* (50 mL). Evaporation of the mixture afforded the sub-title compound as a solid (1 g).

¹H NMR (400 MHz, d₆-DMSO) δ 8.73 (1H, dd,); 7.62 (1H, d); 7.51 (1H, d); 7.13 (1H, dd); 6.36 (2H, s).

MS: APCI(+ve) 213.1/214.9 (M+1)

(b) (βR)-N-(2,6-Dichloro-5-quinolinyl)-β-methyl-benzenepropanamide

To a stirred solution of 2,6-dichloroquinolin-5-amine (prepared as described in 3(a) above) (450 mg) in *N*-methyl pyrrolidinone (6 mL) was added 4-*N,N*-dimethylaminopyridine (512 mg), (*R*)-3-phenylbutyric acid (515 mg) and PyBroP (2 g). The reaction mixture was heated to 50°C for 5 hours. The mixture was cooled to room temperature and poured into

water (10 mL) which was subsequently acidified to pH1 with aqueous 2M hydrochloric acid. The resulting solution was extracted with dichloromethane (3x20 mL). The combined organic extracts were dried, filtered and evaporated. Purification (SiO₂, methanol:dichloromethane 1:10 as eluant) and recrystallisation (ethyl acetate) afforded the sub-title compound as a solid (400 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 10.07 (1H, s), 7.90 (2H, s), 7.63-7.55 (1H, m), 7.47 (1H, d), 7.42-7.25 (5H, m), 3.36-3.27 (1H, m), 2.83 (1H, dd), 2.73 (1H, dd), 1.34 (3H, d).

(c) (βR)-N-[6-Chloro-2-[methyl[3-(methylamino)propyl]amino]-5-quinolinyl]-β-methyl-benzenepropanamide, ditrifluoroacetate

To a stirred solution of (βR)-N-(2,6-dichloro-5-quinolinyl)-β-methyl-benzenepropanamide (Example 3(b)) (200 mg) and potassium carbonate (385 mg) in *N*-methyl pyrrolidinone (2 mL) was added *N,N'*-dimethyl-1,3-propanediamine (570 mg). The mixture was heated at 120°C for 1 hour after which it was cooled and poured into water. The mixture was extracted with dichloromethane and the combined extracts were dried, filtered and evaporated. Purification by HPLC (Waters Symmetry column using 25% to 95% acetonitrile in 0.1% aqueous trifluoroacetic acid) afforded the title product (250 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.91 (1H, s), 8.50 (1H, s), 7.73-7.55 (1H, m), 7.53-7.42 (1H, m), 7.40-7.31 (3H, m), 7.30-7.23 (2H, m), 7.13-7.02 (1H, m), 3.76 (2H, t), 3.31 (1H, q), 3.18 (3H, s), 2.99-2.87 (2H, m), 2.79 (1H, dd), 2.70 (1H, dd), 2.60-2.54 (3H, m), 1.93 (2H, quint.), 1.33 (3H, d).


MS: APCI(+ve) 425.2/427.2 (M+H⁺).

m.p. 159-162°C

Example 4

(βR)-N-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-β-methyl-benzenepropanamide

40




Prepared according to the method of Example 3(c), using (βR)-*N*-(2,6-dichloro-5-quinoliny)- β -methyl-benzenepropanamide (Example 3(b)) (200 mg) and piperazine (580 mg). Purification (SiO_2 , methanol:dichloromethane:ammonium hydroxide solution
5 15:85:1 as eluant) afforded the title compound as a solid (25 mg).

^1H NMR (400 MHz, d_6 -DMSO) δ 9.79 (1H, s), 7.54 (1H, d), 7.44 (1H, d), 7.40-7.22 (6H, m), 7.07 (1H, d), 3.59 (4H, t), 3.38-3.25 (1H, m), 2.82-2.73 (5H, m), 2.68 (1H, dd), 1.33 (3H, d).

10 MS: APCI(+ve) 409.2/411.2 ($\text{M}+\text{H}^+$).
m.p. 194-196°C

Example 5

6-Chloro-2-methyl-*N*-(2-phenylethyl)-5-quinolinecarboxamide



15

Prepared according to the method of Example 1, using 6-chloro-2-methyl-5-quinolinecarboxylic acid (Example 1(a)) (60 mg) and benzeneethanamine (33 mg).

Purification (SiO₂, ethyl acetate:isohexane 3:7 as eluant) afforded the title compound as a solid (15 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.81 (1H, t), 7.93 (1H, d), 7.73 (1H, d), 7.63 (1H, d), 7.40 (1H, d), 7.37-7.23 (5H, m), 3.65 (2H, q), 2.90 (2H, t), 2.65 (3H, s).

MS: APCI(+ve) 325/327 (M+H⁺).

m.p. 170-172°C

Example 6

- 10 (β*R*)-*N*-[6-Chloro-2-[3-(ethylamino)propyl]-5-quinolinyl]-β-methyl-benzenepropanamide, dihydrochloride



(a) [3-[6-Chloro-5-[(3*R*)-1-oxo-3-phenylbutyl]amino]-2-quinolinyl]propyl]ethyl-carbamic acid, 1,1-dimethylethyl ester

- 15 9-Borabicyclo[3.3.1]nonane dimer solution (2.7 mL, 0.5 M in tetrahydrofuran) was added to ethyl(2-propenyl)-carbamic acid, 1,1-dimethylethyl ester (prepared as described in Example 7(iv) of WO 03/041707) (124 mg) at room temperature under nitrogen. The mixture was refluxed for 2 hours after which it was cooled to room temperature. Potassium phosphate (356 mg) in water (1 mL) was added and the mixture stirred for 15 minutes.
- 20 (β*R*)-*N*-(2,6-Dichloro-5-quinolinyl)-β-methyl-benzenepropanamide (Example 3(b)) (200 mg) in *N,N*-dimethylformamide (2 mL) was added followed by *tetrakis*(triphenylphosphine)palladium(0) (7 mg). The reaction mixture was heated to 70°C for 2 hours under nitrogen. On cooling to room temperature the reaction mixture was filtered through diatomaceous earth and the tetrahydrofuran removed under vacuum. The
- 25 resulting mixture was poured into water and extracted with ethyl acetate. The combined

organic extracts were dried, filtered and evaporated. Purification (SiO₂, ethyl acetate:isohexane 30:70 as eluant) gave the sub-title compound (250 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.94 (1H, s), 7.86 (1H, d), 7.77 (1H, d), 7.55-7.45 (1H, m), 7.45-7.21 (6H, m), 3.40-3.26 (1H, m), 3.25-3.09 (4H, m), 2.91-2.78 (3H, m), 2.76-2.65 (1H, m), 1.98-1.90 (2H, m), 1.44-1.27 (12H, m), 1.03 (3H, t).

(b) (βR)-N-[6-Chloro-2-[3-(ethylamino)propyl]-5-quinolinyl]-β-methyl-benzenepropanamide, dihydrochloride

10 [3-[6-Chloro-5-[[[(3R)-1-oxo-3-phenylbutyl]amino]-2-quinolinyl]propyl]ethyl-carbamic acid, 1,1-dimethylethyl ester (Example 6(a)) was dissolved in dichloromethane (3 mL). Hydrochloric acid (HCl) in 1,4-dioxane (4M, 0.8 mL) was added and the mixture stirred for 2 hours. The resultant suspension was evaporated to dryness and recrystallised from methanol / ethyl acetate to give the title compound as a solid (170 mg).

15


¹H NMR (400 MHz, d₆-DMSO) δ 10.18 (1H, s), 8.90 (2H, s), 8.04 (1H, d), 7.92 (1H, d), 7.77-7.67 (1H, m), 7.52 (1H, d), 7.41-7.23 (5H, m), 3.39-3.27 (1H, m), 3.12 (2H, t), 3.02-2.81 (5H, m), 2.75 (1H, dd), 2.15 (2H, quint.), 1.34 (3H, d), 1.20 (3H, t).

MS: APCI(+ve) 410/412 (M+H⁺).

20

Example 7

(βR)-N-[6-Chloro-2-[3-[(3-hydroxypropyl)amino]propyl]-5-quinolinyl]-β-methyl-benzenepropanamide



25

(a) **[3-[6-Chloro-5-[[*(3R)*-1-oxo-3-phenylbutyl]amino]-2-quinolinyl]propyl][3-[[*(1,1*-dimethylethyl)dimethylsilyl]oxy]propyl]-carbamic acid, 1,1-dimethylethyl ester**

Prepared according to the method of example 6(a), using (*βR*)-*N*-(2,6-dichloro-5-quinolinyl)-*β*-methyl-benzenepropanamide (Example 3(b)) (200 mg) and [3-[[*(1,1*-dimethylethyl)dimethylsilyl]oxy]propyl]-2-propenyl-carbamic acid, 1,1-dimethylethyl ester (prepared as described by I. Kadota, S. Saya, Y. Yamamoto, *Heterocycles*, (1997), Vol. 46, pages 335-348) (221 mg). Purification (SiO₂, ethyl acetate:isohexane 1:4 as eluant) afforded the sub-title compound as a solid (300 mg).

¹H NMR (400 MHz, CDCl₃) δ 7.87 (1H, d), 7.62 (1H, d), 7.44-7.08 (5H, m), 7.15 (1H, s), 7.02 (1H, s), 3.62 (2H, t), 3.48 (1H, q), 3.28 (4H, s), 2.94-2.80 (4H, m), 2.08-1.96 (2H, m), 1.74 (2H, s), 1.58 (3H, s), 1.45 (9H, s), 0.88 (9H, s), 0.04 (6H, s).

(b) **(*βR*)-*N*-[6-Chloro-2-[3-[(3-hydroxypropyl)amino]propyl]-5-quinolinyl]-*β*-methyl-benzenepropanamide**

[3-[6-Chloro-5-[[*(3R)*-1-oxo-3-phenylbutyl]amino]-2-quinolinyl]propyl][3-[[*(1,1*-dimethylethyl)dimethylsilyl]oxy]propyl]-carbamic acid, 1,1-dimethylethyl ester (Example 7(a)) was dissolved in dichloromethane (3 mL). HCl in 1,4-dioxane (4M, 1 mL) was added and the mixture stirred for 2 hours. The resultant suspension was evaporated to dryness and the residue was dissolved in dichloromethane (10 mL) and methanol (0.5 mL) and washed with aqueous sodium hydroxide (2M, 3 x 5 mL). The organics were dried, filtered and evaporated. Purification (SiO₂, methanol:dichloromethane:ammonium hydroxide solution 20:80:2 as eluant) afforded the title compound as a solid (85 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.94 (1H, s), 7.86 (1H, d), 7.77 (1H, d), 7.55-7.43 (1H, m), 7.42-7.23 (6H, m), 3.46 (2H, t), 3.40-3.21 (3H, m), 2.92 (2H, t), 2.82 (1H, dd), 2.72 (1H, dd), 2.58-2.47 (2H, m), 1.86 (2H, quint.), 1.55 (2H, quint.), 1.34 (3H, d).


MS: APCI(+ve) 440/442 (M+H⁺).

m.p. 118-120°C

Example 8

3,4-Dichloro-*α*-methyl-*N*-5-quinolinyl-benzenepropanamide

44



Prepared according to the method of Example 1, using 5-aminoquinoline (200 mg) and 3,4-dichloro- α -methyl-benzenepropanoic acid (652 mg). Purification by HPLC (Symmetry
5 - 0.1% aqueous ammonium acetate / acetonitrile) afforded the title compound as a solid (120 mg).


^1H NMR (400 MHz, d_6 -DMSO) δ 9.94 (1H, s), 8.89 (1H, dd), 7.94 (1H, d), 7.85 (1H, d), 7.72 (1H, t), 7.63-7.54 (3H, m), 7.45 (1H, dd), 7.26 (1H, dd), 3.09-2.99 (1H, m), 2.96-2.88
10 (1H, m), 2.78 (1H, dd), 1.23 (3H, d).

MS: APCI(+ve) 359.1/361.1 ($\text{M}+\text{H}^+$).

m.p. 168-170°C

Example 9

15 (βR)-N-[6-Chloro-2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]- β -methyl-benzenepropanamide, dihydrochloride



To a stirred solution of (βR)-*N*-(2,6-dichloro-5-quinolinyl)- β -methyl-benzenepropanamide (Example 3(b)) (200 mg) and potassium carbonate (380 mg) in *N*-methyl pyrrolidinone (2 mL) was added 2-[(2-aminoethyl)amino]-ethanol (580 mg). The mixture was heated at
5 120°C for 3 hours after which it was cooled and poured into water. The resulting solid was isolated by filtration, dried and suspended in dichloromethane (5 mL). The suspension was then treated with di-*tert*-butyl dicarbonate (1.6 g) and stirred for 2 hours. The mixture was poured into water and extracted with dichloromethane (3x20 mL). The combined organic layers were dried and concentrated. Purification (SiO₂, methanol:dichloromethane:


10 ammonium hydroxide solution 2:98:1 as eluant) yielded the desired major isomer which was then dissolved in dichloromethane (5 mL) and treated with HCl in 1,4-dioxane (4M, 1 mL) for 1 hour. The resultant suspension was evaporated to dryness and recrystallised from methanol / ethyl acetate to give the title compound as a colourless solid (50 mg).

15 ¹H NMR (400 MHz, d₆-DMSO) δ 9.69 (1H, s), 7.87 (1H, s), 7.67 (1H, d), 7.47 (1H, d), 7.36-7.28 (4H, m), 7.26-7.19 (1H, m), 6.96-6.89 (1H, m), 3.95-3.86 (2H, m), 3.72 (2H, t), 3.34 (1H, q), 3.28 (2H, t), 3.10 (2H, t), 2.86-2.75 (1H, m), 2.75-2.64 (1H, m), 1.34 (3H, d). MS: APCI(+ve) 427/429 (M+H⁺).

m.p. 178-182°C

20 Example 10

2-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide, dihydrochloride



(a) 4-(5-Amino-6-chloro-2-quinolinyl)-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester

To a stirred solution of 2,6-dichloroquinolin-5-amine (Example 3(a)) (800 mg) and potassium carbonate (2 g) in *N*-methyl pyrrolidinone (4 mL) was added 1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (2 g). The mixture was heated at 130°C for 4 hours after which it was cooled and poured into water. The product was collected by filtration and washed with water to give the sub-title compound as a solid (1.2 g).

¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (1H, d), 7.30 (1H, d), 7.11 (1H, d), 6.82 (1H, d), 5.76 (2H, s), 3.69-3.61 (4H, m), 3.49-3.40 (4H, m), 1.48-1.34 (9H, m).

(b) 2-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide, dihydrochloride

To a stirred solution of 2-chloro-benzenepropanoic acid (204 mg) in dichloromethane (2 mL) at 0°C under nitrogen, was added *N,N*-dimethylformamide (1 drop) and oxalyl chloride (0.3 mL). The reaction mixture was heated to reflux for 2 hours, then cooled, evaporated to dryness and redissolved in dichloromethane (1 mL). This solution was added to a stirred solution of 4-(5-amino-6-chloro-2-quinolinyl)-piperazinecarboxylic acid, 1,1-dimethylethyl ester (Example 10(a)) (200 mg) and potassium carbonate (380 mg) in acetone (2 mL). The reaction mixture was stirred at room temperature for 16 hours then the acetone was evaporated. The residue was redissolved in dichloromethane then poured into water and extracted with dichloromethane (3x20 mL). The combined organic extracts were dried, filtered and evaporated. The resulting solid was purified (SiO₂, methanol: dichloromethane: ammonium hydroxide solution 10:90:1 as eluant) then redissolved in methanol and treated with HCl in 1,4-dioxane (4M, 1 mL) for 1 hour. The resultant suspension was evaporated to dryness and recrystallised from methanol / ethyl acetate to give the title compound as a solid (90 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 10.09 (1H, s), 9.40 (2H, s), 7.89 (1H, d), 7.83-7.69 (2H, m), 7.50-7.26 (5H, m), 4.04 (4H, s), 3.25 (4H, s), 3.08 (2H, t), 2.83 (2H, t).

MS: APCI(+ve) 429 (M+H⁺).

m.p. 265-270°C

Example 11

2,4-Dichloro-N-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,
5 dihydrochloride



Prepared according to method of Example 10(b) using 4-(5-amino-6-chloro-2-quinolinyl)-
1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (Example 10(a)) (200 mg) and 2,4-
10 dichloro-benzenepropanoic acid (242 mg). Purification by HPLC (Symmetry - 0.1 %
aqueous ammonium acetate / acetonitrile), treatment with HCl in 1,4-dioxane (4M, 1 mL)
and recrystallisation (methanol/ethyl acetate) afforded the title compound as a solid (29
mg).

¹H NMR (400 MHz, d₆-DMSO) δ 10.10 (1H, s), 9.39 (2H, s), 7.90 (1H, d), 7.83-7.67 (2H,
15 m), 7.63 (1H, s), 7.50-7.33 (3H, m), 4.03 (4H, s), 3.25 (4H, s), 3.06 (2H, t), 2.82 (2H, t).


MS: APCI(+ve) 463(M+H⁺).

m.p. 200°C (dec)

Example 12

4-Chloro-N-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,
20 dihydrochloride

48




Prepared according to method of Example 10(b) using 4-(5-amino-6-chloro-2-quinolinyl)-
1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (Example 10(a)) (200 mg) and
4-chloro-benzenepropanoic acid (204 mg). Purification (SiO₂, methanol:dichloromethane:
5 ammonium hydroxide solution 10:90:1 as eluant), treatment with HCl in 1,4-dioxane (4M,
1 mL) and recrystallisation (ethyl acetate/*iso*-hexane) afforded the title compound as a
solid (17 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.68 (1H, s), 9.30 (1H, s), 7.79 (1H, d), 7.64-7.58 (2H,
10 m), 7.37-7.28 (4H, m), 7.23 (1H, d), 3.98 (4H, t), 3.23 (4H, s), 2.99 (2H, t), 2.78 (2H, m).
MS: APCI(+ve) 429/431 (M+H⁺).
m.p. 183-188°C

Example 13

15 (β*R*)-*N*-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]-β-methyl-
benzenepropanamide



To a 10 mL microwave vial was added (βR)-*N*-(2,6-dichloro-5-quinolinyl)- β -methyl-benzenepropanamide (Example 3(b)) (200 mg), (3*S*)-3-pyrrolidinamine (145 mg), triethylamine (0.085 mL) and acetonitrile (5 mL). The vial was sealed and heated at 100°C for 1 hour within a microwave. The reaction was cooled to room temperature and
5 evaporated. Purification (SiO₂, methanol:dichloromethane:ammonium hydroxide solution 10:90:1 as eluant) afforded the title compound as a solid (80 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 9.77 (1H, s), 7.51 (1H, d), 7.43 (1H, d), 7.39-7.30 (5H, m), 7.29-7.23 (1H, m), 6.71 (1H, d), 3.69-3.46 (4H, m), 3.38-3.26 (1H, m), 3.24-3.14 (1H, m), 2.77 (1H, dd), 2.67 (1H, dd), 2.12-2.01 (1H, m), 1.78-1.68 (1H, m), 1.33 (3H, d).

MS: APCI(+ve) 409/411 (M+H⁺).

m.p. 204-207°C

Example 14

15 *N*-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-2-methoxy-benzenepropanamide




Prepared according to method of Example 10(b) using 4-(5-amino-6-chloro-2-quinolinyl)-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (Example 10(a)) (200 mg) and 2-methoxy-benzenepropanoic acid (200 mg). Purification by HPLC (Waters Symmetry
20 column using 5% to 50% acetonitrile in 0.1% aqueous trifluoroacetic acid) and recrystallisation (methanol/ethyl acetate) afforded the title compound as a solid (25 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.90 (1H, s), 9.10 (2H, s), 7.78 (1H, d), 7.66 (1H, d), 7.58 (1H, d), 7.34-7.19 (3H, m), 7.00 (1H, d), 6.92 (1H, t), 3.95 (4H, s), 3.83 (3H, s), 3.23
25 (4H, s), 2.94 (2H, t), 2.74 (2H, t).

MS: APCI(+ve) 425/427 (M+H⁺).

Example 15

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(3-hydroxypropyl)amino]-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide



(a) (βR)-*N*-[6-Chloro-2-[(3*R*)-3-hydroxy-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide

To a 10 mL microwave vial was added (βR)-*N*-(2,6-dichloro-5-quinoliny)- β -methyl-benzenepropanamide (Example 3(b)) (300 mg), (3*R*)-3-pyrrolidinol (220 mg) and acetonitrile (5 mL). The vial was sealed and heated at 100°C for 45 minutes within a microwave. The reaction was cooled to room temperature and the resulting solid removed by filtration and washed with acetonitrile to afford the sub-title compound (340 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 9.78 (1H, s), 7.51 (1H, d), 7.44 (1H, d), 7.40-7.31 (5H, m), 7.29-7.23 (1H, m), 6.74 (1H, d), 4.99 (1H, s), 4.41 (1H, s), 3.63-3.53 (2H, m), 3.39-3.22 (3H, m), 2.77 (1H, dd), 2.68 (1H, dd), 2.11-1.98 (1H, m), 1.97-1.88 (1H, m), 1.33 (3H, d).

(b) (βR)-*N*-[6-Chloro-2-[(3*R*)-3-[(methylsulfonyl)oxy]-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide

To a stirred solution of (βR)-*N*-[6-chloro-2-[(3*R*)-3-hydroxy-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide (Example 15(a)) (340 mg) in dichloromethane was added methanesulphonyl chloride (0.26 mL) and triethylamine (0.46 mL). The reaction was

stirred for 12 hours under nitrogen and then purified (SiO₂, methanol:dichloromethane: ammonium hydroxide solution 10:90:1 as eluant) to afford the sub-titled compound (250 mg).

5 ¹H NMR (400 MHz, d₆-DMSO) δ 9.80 (1H, s), 7.55 (1H, d), 7.48 (1H, d), 7.44-7.32 (5H, m), 7.30-7.23 (1H, m), 6.81 (1H, d), 5.45 (1H, s), 3.93-3.69 (3H, m), 3.64-3.51 (1H, m), 3.35-3.29 (1H, m), 3.27 (3H, s), 2.78 (1H, dd), 2.68 (1H, dd), 2.38-2.28 (2H, m), 1.33 (3H, d).

10 (c) **(βR)-N-[6-Chloro-2-[(3S)-3-[(3-hydroxypropyl)amino]-1-pyrrolidinyl]-5-quinolinyl]-β-methyl-benzenepropanamide**

To a 10 mL vial was added (βR)-N-[6-chloro-2-[(3R)-3-[(methylsulfonyl)oxy]-1-pyrrolidinyl]-5-quinolinyl]-β-methyl-benzenepropanamide (Example 15(b)) (130 mg), 3-amino-1-propanol (0.5 mL) and acetonitrile (3 mL). The vial was sealed and heated at
15 100°C for 90 minutes within a microwave. The reaction was cooled to room temperature and evaporated. Purification (SiO₂, methanol:dichloromethane 1:9 as eluant) and recrystallisation (acetonitrile) afforded the title compound as a solid (21 mg).

¹H NMR (400 MHz, CD₃OD) δ 7.47 (1H, d), 7.41 (1H, d), 7.30-7.24 (4H, m), 7.23-7.16
20 (1H, m), 7.02 (1H, d), 6.56 (1H, d), 3.78-3.71 (1H, m), 3.68-3.61 (1H, m), 3.56 (2H, t), 3.51-3.35 (2H, m), 3.33-3.24 (2H, m), 2.82-2.73 (1H, m), 2.71-2.64 (3H, m), 2.25-2.14 (1H, m), 1.90-1.77 (1H, m), 1.67 (2H, dt), 1.32 (3H, d).

MS: APCI(+ve) 467/469 (M+H⁺).


m.p. 155-158°C

25

Example 16

(βR)-N-[6-Chloro-2-[(3S)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinyl]-β-methyl-benzenepropanamide, dihydrochloride.

30



a) (βR)-N-[6-Chloro-2-[(3S)-3-[[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]-1-pyrrolidinyl]-5-quinoliny]-β-methyl-benzenepropanamide

A suspension of N-[2-[(3S)-3-amino-1-pyrrolidinyl]-6-chloro-5-quinoliny]-β-methyl-, (βR)- benzenepropanamide (Example 13) (400 mg) and activated 3 Å molecular sieves (500 mg) in methanol (10 mL) was treated with (*tert*-butyldimethylsilyloxy)acetaldehyde (0.17 mL) and the resulting mixture stirred at room temperature for 6 hours. Sodium triacetoxyborohydride (416 mg) was added and the mixture stirred for 16 hours. The reaction mixture was concentrated to dryness. Purification (SiO₂, ethyl acetate:*iso*hexane 1:1 as eluant) gave the sub-title compound as a solid (250 mg).

¹H NMR (400 MHz, CD₃OD) δ 7.52 (1H, d), 7.46 (1H, d), 7.35-7.19 (6H, m), 7.06 (1H, d), 6.61 (1H, d), 3.84-3.63 (4H, m), 3.59-3.48 (2H, m), 3.43-3.28 (2H, m), 2.87-2.64 (4H, m), 2.33-2.20 (1H, m), 1.97-1.84 (1H, m), 1.37 (3H, d), 0.85 (9H, s), 0.04 (6H, s).

b) (βR)-N-[6-Chloro-2-[(3S)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinoliny]-β-methyl-benzenepropanamide, dihydrochloride

Trifluoroacetic acid (2 mL) was added to a stirred solution of (βR)-N-[6-chloro-2-[(3S)-3-[[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]-1-pyrrolidinyl]-5-quinoliny]-β-methyl-benzenepropanamide (Example 16(a)) (250 mg) in dichloromethane (5 mL). The mixture was stirred at room temperature for 5 hours then concentrated. Purification (SiO₂,

dichloromethane:methanol:7N ammonia in methanol 97:2:1 as eluant) and further purification (Varian SCX cartridge using methanol (100 mL) and then 7N ammonia in methanol (100 mL) as eluant) gave the title compound as a solid (40 mg).


- 5 ¹H NMR (400 MHz, CD₃OD) δ 7.47 (1H, d), 7.41 (1H, d), 7.31-7.24 (4H, m), 7.20 (1H, quintet), 7.02 (1H, d), 6.56 (1H, d), 3.75 (1H, dd), 3.69-3.56 (3H, m), 3.52-3.42 (2H, m), 3.37-3.24 (2H, m), 2.83-2.63 (4H, m), 2.28-2.15 (1H, m), 1.94-1.80 (1H, m), 1.32 (3H, d).
MS: APCI(+ve) 453.2/455.2 (M+H⁺).
m.p. 177-182°C.

10

Example 17

N-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide

15



- Prepared according to the method of Example 10(b) using 4-(5-amino-6-chloro-2-quinolinyl)-1-piperazinecarboxylic acid, 1,1-dimethylethyl ester (Example 10(a)) (200 mg)
20 and benzenepropanoic acid (166 mg). Purification (SiO₂, dichloromethane:methanol:7N ammonia in methanol 90:10:1 as eluant) and recrystallisation from acetonitrile gave the title compound as a solid (17 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 9.86 (1H, s), 7.66-7.55 (2H, m), 7.49 (1H, d), 7.38-7.28 (4H, m), 7.28-7.22 (1H, m), 7.18 (1H, d), 3.75-3.66 (4H, m), 3.03-2.89 (6H, m), 2.82-2.72 (2H, m).

MS: APCI(+ve) 395/397 (M+H⁺).

5 m.p. 231-234°C

Example 18

10 *N*-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]-2-chloro-benzenepropanamide



a) 2-Chloro-*N*-(2,6-dichloro-5-quinolinyl)-benzenepropanamide

15 To a stirred solution of 2-chloro-benzenepropanoic acid (1 g) in dichloromethane (5 mL) at 0°C under nitrogen, was added *N,N*-dimethylformamide (1 drop) and oxalyl chloride (2.4 mL). The reaction mixture was stirred at room temperature for 2 hours, then evaporated to dryness and redissolved in dichloromethane (2 mL). The solution was added to a mixture of 2,6-dichloroquinoline-5-amine (prepared as described in WO2003080579) (400 mg) and potassium carbonate (522 mg) in acetone (10 mL). The reaction mixture was stirred at
20 room temperature for 2 hours. The resulting solid was collected by filtration and subsequently washed with water (10 mL) to give the sub-title compound (420 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 10.19 (1H, s), 8.08 (1H, d), 7.93 (2H, s), 7.63 (1H, d), 7.52-7.40 (2H, m), 7.37-7.27 (2H, m), 3.09 (2H, t), 2.85 (2H, t).

MS: APCI(+ve) 379 (M+H⁺).

5 b) *N*-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]-2-chloro-
benzenepropanamide

Prepared according to the method of Example 13 using 2-chloro-*N*-(2,6-dichloro-5-quinolinyl)-benzenepropanamide (Example 18(a)) (420 mg) and (3*S*)-3-pyrrolidinamine (287 mg). Purification (SiO₂, dichloromethane:methanol:7N ammonia in methanol 90:10:1 as eluant) gave the title compound as a solid (335 mg).


¹H NMR (400 MHz, CD₃OD) δ 7.58-7.39 (3H, m), 7.37-7.26 (2H, m), 7.22-7.13 (2H, m), 6.71 (1H, d), 3.74-3.62 (2H, m), 3.62-3.47 (2H, m), 3.26 (1H, dd), 3.11 (2H, t), 2.80 (2H, t), 2.24-2.10 (1H, m), 1.87-1.73 (1H, m).

15 MS: APCI(+ve) 429/431 (M+H⁺).

m.p. 200-212°C

Example 19

20 **2-Chloro-N-[6-chloro-2-[(3S)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinyl]-benzenepropanamide**



a) 2-Chloro-*N*-[6-chloro-2-[(3*S*)-3-[[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]-1-pyrrolidinyl]-5-quinolinyl]-benzenepropanamide

Prepared according to the method of Example 16(a) using *N*-[2-[(3*S*)-3-amino-1-pyrrolidinyl]-6-chloro-5-quinolinyl]-2-chloro-benzenepropanamide (Example 18) (300 mg) and (*tert*-butyldimethylsilyloxy)acetaldehyde (0.12 mL). Purification (SiO₂, Ethyl acetate:isohexane 2:1 as eluant) gave the sub-title compound (200 mg).

¹H NMR (400 MHz, CD₃OD) δ 7.56-7.50 (2H, m), 7.45 (1H, d), 7.36-7.27 (2H, m), 7.21-7.14 (2H, m), 6.73 (1H, d), 3.81-3.62 (4H, m), 3.56-3.45 (2H, m), 3.41-3.35 (1H, m), 3.12 (2H, t), 2.85-2.72 (4H, m), 2.29-2.19 (1H, m), 1.92-1.83 (1H, m), 0.81 (9H, s), 0.01 (6H, s).

b) 2-Chloro-*N*-[6-chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinyl]-benzenepropanamide

Hydrochloric acid (2 mL, 4 M solution in 1,4-dioxane) was added to a stirred solution of 2-chloro-*N*-[6-chloro-2-[(3*S*)-3-[[2-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]-1-pyrrolidinyl]-5-quinolinyl]-benzenepropanamide (Example 19(a)) (200 mg). The mixture was stirred at room temperature under nitrogen for 45 minutes then concentrated. Purification (SiO₂, dichloromethane: methanol:7N ammonia in methanol 93:7:1 as eluant) gave the title compound as a solid (77 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 9.86 (1H, s), 7.67 (1H, d), 7.54 (1H, d), 7.50-7.39 (3H, m), 7.37-7.25 (2H, m), 6.85 (1H, d), 4.49 (1H, t), 3.75-3.25 (6H, m), 3.08 (2H, t), 2.79 (2H, t), 2.65 (2H, t), 2.19-2.05 (1H, m), 1.92-1.75 (1H, m).

MS: APCI(+ve) 473/475 (M+H⁺).

m.p. 180-182°C

Example 20

1-[6-Chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinolinyl]-4-piperidinecarboxylic acid, potassium salt



5

a) 1-(5-Amino-6-chloro-2-quinolinyl)-4-piperidinecarboxylic acid ethyl ester

Prepared according to the method of Example 13 using 2,6-dichloro-5-quinolinamine (prepared as described in WO2003080579) (800 mg) and 4-piperidinecarboxylic acid, ethyl ester (1.8 g). Purification (SiO₂, dichloromethane:methanol 99:1 as eluant) gave sub-
10 title compound as a solid (900 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.34 (1H, d), 7.29 (1H, d), 7.14 (1H, d), 6.78 (1H, d), 5.84 (2H, s), 4.40 (2H, d), 4.07 (2H, q), 3.03 (2H, t), 2.69-2.58 (1H, m), 1.90 (2H, d), 1.55 (2H, q), 1.19 (3H, t).

15 MS: APCI(+ve) 334/336 (M+H⁺).

b) 1-[6-Chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinolinyl]-4-piperidinecarboxylic acid, ethyl ester

Prepared according to the method of Example 18 (a) using 1-(5-amino-6-chloro-2-
20 quinolinyl)-4-piperidinecarboxylic acid ethyl ester (Example 20(a)) (200 mg) and 2-chloro-benzenepropanoic acid (330 mg). Solid product was collected by filtration and washed with water to give the sub-title compound (230 mg).

¹H NMR (400 MHz, CD₃OD) δ 9.91 (1H, s), 7.71 (1H, d), 7.58 (1H, d), 7.53-7.40 (3H, m), 7.38-7.21 (3H, m), 4.43 (2H, d), 4.08 (2H, q), 3.17-3.03 (4H, m), 2.80 (2H, t), 2.72-2.62 (1H, m), 1.93 (2H, d), 1.57 (2H, q), 1.19 (3H, t).

5 MS: APCI(+ve) 500/502 (M+H⁺).

c) 1-[6-Chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinolinyl]-4-piperidinecarboxylic acid, potassium salt

10 Potassium hydroxide (100 mg), in water (1 mL) was added to a solution of 1-[6-chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinolinyl]-4-piperidinecarboxylic acid, ethyl ester (Example 20(b)) (230 mg) in methanol (2 mL), in a 10 mL vial. The vial was sealed and heated at 70°C for 10 minutes within a microwave. The reaction mixture was concentrated and water (10 mL) was added to the residue. The solid was collected by filtration to give the title compound (160 mg).

15

¹H NMR (300 MHz, d₆-DMSO) δ 7.73 (1H, d), 7.53-7.38 (4H, m), 7.32-7.20 (2H, m), 7.10 (1H, d), 4.27-4.13 (2H, m), 3.22-2.91 (4H, m), 2.82-2.68 (2H, m), 2.06-1.95 (1H, m), 1.84-1.71 (2H, m), 1.66-1.49 (2H, m).


MS: APCI(+ve) 472/474 (M+H⁺).

20

Example 21

2-[(3S)-3-Amino-1-pyrrolidinyl]-6-chloro-N-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide

25



a) 6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide

To a solution of 5-bromo-6-chloroquinoline (prepared according to the method of Journal of Heterocyclic Chemistry 1967, 4, 410) (3 g), 2-chloro-benzeneethanamine (3.8 g) and triethylamine (1.9 mL) in *N*-methyl pyrrolidinone (12 mL) was added dichlorobis(triphenylphosphine)palladium(II) (1.2 g). The mixture was heated with stirring at 100°C under a 6 bar pressure of carbon monoxide for 16 hours after which it was cooled and filtered through diatomaceous earth, washing with methanol. The combined organics were concentrated and the residue was partitioned between dichloromethane (100 mL) and water (100 mL). The layers were separated and the aqueous was extracted with dichloromethane (2x100 mL). The combined organics were washed with 2M aqueous hydrochloric acid (50 mL) and saturated aqueous sodium hydrogen carbonate (50 mL) and then dried, filtered and evaporated. Purification (SiO₂, dichloromethane:methanol 95:5 as eluant) gave the sub-title compound as a solid (2 g).

¹H NMR (400 MHz, d₆-DMSO) δ 9.00 - 8.86 (2H, m), 8.06 (1H, d), 7.92-7.77 (2H, m), 7.63-7.53 (1H, m), 7.52-7.38 (2H, m), 7.36-7.24 (2H, m), 3.77-3.60 (2H, m), 3.10-2.98 (2H, m).

b) 6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide 1-oxide

To a stirred solution of 6-chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide (Example 21(a)) (2 g) in acetic acid (20 mL) was added peracetic acid 36-40 wt. % solution in acetic acid (10 mL). The mixture was stirred at room temperature for 16 hours then added to a solution of 10 % aqueous sodium sulfite (100 mL) which was subsequently

extracted with dichloromethane (3x100 mL). The combined extracts were washed with saturated aqueous sodium hydrogen carbonate (2x50 mL), dried, filtered and evaporated. Purification (SiO₂, dichloromethane:methanol 98:2 as eluant) gave the sub-title compound as a solid (1 g).

5

¹H NMR (400 MHz, d₆-DMSO) δ 8.97 (1H, t), 8.63 (1H, d), 8.55 (1H, d), 7.87 (1H, d), 7.54-7.37 (4H, m), 7.35-7.27 (2H, m), 3.67 (2H, q), 3.04 (2H, t).
MS: APCI(+ve) 361 (M+H⁺).

10 **c) 2,6-Dichloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide**

Phosphorus oxychloride (6 mL) was added drop wise to a suspension of 6-chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide 1-oxide (Example 21(b)) (1 g) in dichloromethane (3 mL) at 0°C. The reaction mixture was then heated to 60°C for 2 hours then allowed to cool and concentrated. The residue was partitioned between

15 dichloromethane (100 mL) and ice water (50 mL). The organic layer was separated and the aqueous layer was extracted with dichloromethane (3x50 mL). The combined organics were washed with saturated aqueous sodium hydrogen carbonate (50 mL), dried, filtered and evaporated. Purification (SiO₂, ethyl acetate:isohexane 1:3 as eluant) gave the sub-title compound (700 mg).

20

¹H NMR (400 MHz, d₆-DMSO) δ 8.94 (1H, t), 8.01 (1H, d), 7.90 (2H, t), 7.65 (1H, d), 7.50-7.40 (2H, m), 7.35-7.28 (2H, m), 3.67 (2H, q), 3.03 (2H, t).
MS: APCI(+ve) 379/381 (M+H⁺).

25 **d) 2-[(3*S*)-3-Amino-1-pyrrolidiny]-6-chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide**

Prepared according to the method of Example 13 using 2,6-dichloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide (500 mg) and (3*S*)-3-pyrrolidinamine (354 mg). Purification (SiO₂, dichloromethane:methanol:7*N* ammonia in methanol 95:5:1) gave
30 the title compound as a solid (450 mg).


¹H NMR (400 MHz, d₆-DMSO) δ 8.77 (1H, t), 7.57-7.39 (5H, m), 7.35-7.27 (2H, m), 6.85 (1H, d), 3.72-3.47 (6H, m), 3.27-3.13 (1H, m), 3.01 (2H, t), 2.13-2.01 (1H, m), 1.80-1.64 (3H, m).

MS: APCI(+ve) 429/431 (M+H⁺).

5 m.p. 196-198°C.

Example 22

10 **6-Chloro-N-[2-(2-chlorophenyl)ethyl]-2-[(3S)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinecarboxamide**



15 **a) 6-Chloro-N-[2-(2-chlorophenyl)ethyl]-2-[(3S)-3-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]-1-pyrrolidinyl]-5-quinolinecarboxamide**

Prepared according to the method of Example 16(a) using 2-[(3S)-3-amino-1-pyrrolidinyl]-6-chloro-N-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide (Example 21) (300 mg) and (*tert*-butyldimethylsilyloxy)acetaldehyde (0.12 mL). Purification (SiO₂, dichloromethane:methanol 95:5 as eluant) gave the sub-title compound (320 mg).

20

¹H NMR (400 MHz, d₆-DMSO) δ 8.77 (1H, t), 7.56-7.39 (5H, m), 7.34-7.26 (2H, m), 6.87 (1H, d), 3.76-3.19 (9H, m), 3.01 (2H, t), 2.74-2.63 (2H, m), 2.18-2.05 (1H, m), 1.87-1.75 (1H, m), 0.86 (9H, s), 0.04 (6H, s).

b) 6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinecarboxamide

Prepared according to the method of Example 19(b) using 6-chloro-*N*-[2-(2-

- 5 chlorophenyl)ethyl]-2-[(3*S*)-3-[[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]amino]-1-pyrrolidinyl]-5-quinolinecarboxamide (Example 22(a)) (320 mg). Purification by HPLC (Symmetry 0.1 % aqueous trifluoroacetic acid/acetonitrile) gave the title compound as a solid (69 mg).

- 10 ¹H NMR (300 MHz, d₆-DMSO) δ 8.77 (1H, t), 7.59-7.38 (5H, m), 7.36-7.25 (2H, m), 6.87 (1H, d), 4.51 (1H, s), 3.77-3.19 (7H, m), 3.01 (2H, t), 2.66 (2H, t), 2.20-2.05 (1H, m), 1.91-1.77 (1H, m).


MS: APCI(+ve) 473/475 (M+H⁺).

m.p. 170-172°C.

15

Example 23

1-[6-Chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid



20

a) 5-Bromo-2,6-dichloro-quinoline

2,6-Dichloroquinoline (30 g) and aluminium trichloride (60 g) were heated to 120°C with stirring under a nitrogen atmosphere. Bromine (9.2 mL) was added dropwise over 1 hour and the mixture was then stirred at 120°C for 1 hour before being cooled to room temperature. A methanol / deionised water mixture (150 mL, 1:1) was then slowly added and the mixture was concentrated *in vacuo*. Dichloromethane (500 mL) and deionised water (250 mL) were added, the layers were separated and the aqueous fraction was extracted with dichloromethane (2 x 250 mL). The combined organic extracts were washed with saturated aqueous sodium hydrogen carbonate (250 mL) before being dried, filtered and concentrated. Purification by chromatography (SiO₂, isohexane: dichloromethane 7:3 as eluant) gave the sub-title compound as a solid (27 g).

¹H NMR (400 MHz, CDCl₃) δ 8.53 (1H, d), 7.94 (1H, d), 7.78 (1H, d), 7.50 (1H, d).
MS: APCI(+ve) 276/278/280/282 (M+H⁺).

b) 2,6-Dichloro-5-quinolinecarboxylic acid

To a stirred solution of 5-bromo-2,6-dichloro-quinoline (23 g) in tetrahydrofuran (300 mL) at 0°C was added *iso*-propylmagnesium chloride (2M in tetrahydrofuran, 42 mL) over 2 hours. CO₂ was bubbled through the solution for 20 minutes and then methanol (20 mL) was added. The mixture was poured into water (500 mL) and extracted with ethyl acetate. The aqueous layer was acidified with hydrochloric acid (2M in water) to pH2-3 and the resulting solid collected by filtration. The solid was washed with water and dried to afford the sub-titled compound (11.5g).

¹H NMR (400 MHz, d₆-DMSO) δ 8.29 (1H, d), 8.07 (1H, d), 7.94 (1H, d), 7.74 (1H, d).

c) 6-Chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid

Prepared according to the method of Example 13 using 2,6-dichloro-5-quinolinecarboxylic acid (Example 23(b)) (800 mg) and 4-piperidinecarboxylic acid, ethyl ester (2.7 g). Purification (SiO₂, dichloromethane:methanol 99:1 as eluant) and further purification (Varian NH₂ cartridge using methanol (100 mL) and then 5 % acetic acid in methanol (100 mL) as eluant) gave sub-title compound as a solid (900 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 7.85 (1H, d), 7.62-7.53 (2H, m), 7.38 (1H, d), 4.43 (2H, d), 4.08 (2H, q), 3.11 (2H, t), 2.72-2.60 (1H, m), 1.97-1.87 (2H, m), 1.56 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 363/365 (M+H⁺).

5

d) 1-[6-Chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester

Prepared according to the method of Example 1(b) using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and 2,6-dichlorobenzenepropanoic acid (323 mg). Purification (SiO₂, dichloromethane:methanol 99:1 as eluant) gave the sub-title compound (240 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.87 (1H, t), 7.67 (1H, d), 7.58-7.48 (4H, m), 7.36-7.30 (2H, m), 4.43 (2H, d), 4.08 (2H, q), 3.56 (2H, q), 3.21 (2H, t), 3.11 (2H, t), 2.73-2.60 (1H, m), 1.93 (2H, d), 1.56 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 534/536 (M+H⁺).

e) 1-[6-Chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 23(b)) (240 mg). The reaction mixture was acidified to pH5 using 2 M aqueous hydrochloric acid and the solid was collected by filtration. Purification (Varian NH₂ cartridge using methanol (100 mL) and then 5 % acetic acid in methanol (100 mL) as eluant) gave the title compound as a solid (115 mg).

¹H NMR (300 MHz, d₆-DMSO) δ 8.92-8.80 (1H, m), 7.66 (1H, d), 7.57-7.44 (4H, m), 7.38-7.28 (2H, m), 4.42 (2H, d), 3.66-3.46 (2H, m), 3.27-2.97 (5H, m), 2.01-1.81 (2H, m), 1.64-1.45 (2H, m).


MS: APCI(+ve) 506 (M+H⁺).

m.p. 262-264°C.

30

Example 24**1-[6-Chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid**

5

**a) 1-[6-Chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester**

Prepared according to the method of Example 1 using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and 2-chloro-benzeneethanamine (265 mg). Purification (SiO₂, dichloromethane:methanol 99:1 as eluant) gave the sub-title compound (160 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.77 (1H, t), 7.60-7.39 (5H, m), 7.35-7.24 (3H, m), 4.42 (2H, d), 4.08 (2H, q), 3.63 (2H, q), 3.10 (2H, t), 3.01 (2H, t), 2.73-2.62 (1H, m), 1.92 (2H, d), 1.55 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 500/502 (M+H⁺).

b) 1-[6-Chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester


(Example 24(a)) (160 mg). Reaction mixture was acidified to pH5 using 2 M aqueous hydrochloric acid and the solid was collected by filtration. Purification (Varian NH₂ cartridge using methanol: dichloromethane 1:1 (100 mL) and then acetic acid:methanol:dichloromethane 1:10:10 (100 mL) as eluant) gave the title compound as a solid (70 mg).

¹H NMR (300 MHz, d₆-DMSO) δ 8.76 (1H, t), 7.61-7.38 (5H, m), 7.37-7.23 (3H, m), 4.41 (2H, d), 3.63 (2H, q), 3.16-2.96 (4H, m), 2.63-2.39 (1H, m), 1.95-1.84 (2H, m), 1.65-1.43 (2H, m).

MS: APCI(-ve) 470/472 (M-H⁺).
m.p. 250-253°C.

Example 25

1-[6-Chloro-5-[[(2,2-diphenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid, acetate



a) 1-[6-Chloro-5-[[(2,2-diphenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester

Prepared according to the method of Example 1 using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and β-phenyl-

benzeneethanamine (335 mg). Purification (SiO₂, dichloromethane as eluant) gave the sub-title compound (250 mg).

¹H NMR (300 MHz, d₆-DMSO) δ 8.78-8.68 (1H, m), 7.55-6.95 (14H, m), 4.45-4.30 (3H, m), 4.14-3.96 (4H, m), 3.20-2.98 (2H, m), 2.76-2.59 (1H, m), 2.01-1.81 (2H, m), 1.54 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 542/544 (M+H⁺).

b) 1-[6-Chloro-5-[[2,2-diphenylethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid, acetate

Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[[2,2-diphenylethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 25(a)) (250 mg). Reaction mixture was acidified to pH 5 using 2M aqueous hydrochloric acid and the solid was collected by filtration. Purification (Varian NH₂ cartridge using methanol (100 mL) and then 5 % acetic acid in methanol (100 mL) as eluant) gave the title compound as a solid (160 mg).


¹H NMR (300 MHz, d₆-DMSO) δ 8.73 (1H, t), 7.53-7.19 (12H, m), 7.10 (1H, d), 6.99 (1H, d), 4.46-4.27 (3H, m), 4.01 (2H, t), 3.04 (2H, t), 2.59-2.33 (1H, m), 1.98-1.74 (2H, m), 1.62-1.40 (2H, m).

MS: APCI(-ve) 512/514 (M-H⁺).

m.p. 180-185°C.

Example 26

1-[6-Chloro-5-[(2-phenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid



a) 1-[6-Chloro-5-[(2-phenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester

5 Prepared according to the method of Example 1 using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and benzeneethanamine (175 mg). The resulting solid was recrystallised from acetonitrile to give the sub-title compound (200 mg).

10 ¹H NMR (400 MHz, d₆-DMSO) δ 8.71 (1H, t), 7.57-7.47 (3H, m), 7.37-7.19 (6H, m), 4.41 (2H, d), 4.08 (2H, q), 3.60 (2H, q), 3.10 (2H, t), 2.88 (2H, t), 2.72-2.62 (1H, m), 1.93 (2H, d), 1.55 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 466/468 (M+H⁺).

15 **b) 1-[6-Chloro-5-[(2-phenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid**


Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[(2-phenylethyl)amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 26(a)) (200 mg). The reaction mixture was acidified to pH 5 using 2M aqueous
20 hydrochloric acid and the solid was collected by filtration and washed with water to give the title compound (110 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 12.26 (1H, s), 8.72 (1H, t), 7.59-7.46 (3H, m), 7.36-7.20 (6H, m), 4.41 (2H, d), 3.60 (2H, q), 3.11 (2H, t), 2.88 (2H, t), 2.62-2.53 (1H, m), 1.92 (2H, d), 1.55 (2H, q).

- 5 MS: APCI(-ve) 436/438 (M-H⁺).
m.p. 260-262°C.

Example 27

- 10 **1-[6-Chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid**



- 15 **a) 1-[6-Chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester**
Prepared according to the method of Example 1(b) using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and 2-fluorobenzeneethanamine (216 mg). The resulting solid was recrystallised from acetonitrile to give the sub-title compound (260 mg).

20

¹H NMR (400 MHz, d₆-DMSO) δ 8.75 (1H, t), 7.57-7.49 (3H, m), 7.41-7.14 (5H, m), 4.42 (2H, d), 4.08 (2H, q), 3.61 (2H, q), 3.10 (2H, t), 2.92 (2H, t), 2.67 (1H, tt), 1.92 (2H, d), 1.55 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 484/486 (M+H⁺).

b) 1-[6-Chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

5 Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 27(a)) (260 mg). The reaction mixture was acidified to pH 5 using 2M aqueous hydrochloric acid and the solid was collected by filtration and washed with water to give the title compound (125 mg).

10 ¹H NMR (400 MHz, d₆-DMSO) δ 8.75 (1H, t), 7.57-7.49 (3H, m), 7.41-7.14 (5H, m), 4.41 (2H, d), 3.60 (2H, q), 3.09 (2H, t), 2.92 (2H, t), 2.61-2.52 (1H, m), 1.92 (2H, d), 1.53 (2H, q).


MS: APCI(-ve) 454/456 (M-H⁺).

15 m.p. 270-272°C.

Example 28

1-[6-Chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

20



a) 1-[6-Chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester

Prepared according to the method of Example 1 using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and 2-methylbenzeneethanamine (164 mg). The resulting solid was recrystallised from acetonitrile to give the sub-title compound (180 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.76 (1H, t), 7.60-7.51 (3H, m), 7.29-7.13 (5H, m), 4.42 (2H, d), 4.08 (2H, q), 3.54 (2H, q), 3.10 (2H, t), 2.88 (2H, t), 2.73-2.62 (1H, m), 2.35 (3H, s), 1.93 (2H, d), 1.55 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 480/482 (M+H⁺).

b) 1-[6-Chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 28(a)) (180 mg). The reaction mixture was acidified to pH 5 using 2M aqueous hydrochloric acid and the solid was collected by filtration and washed with water to give the title compound (120 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.88 (1H, s), 8.04-7.83 (1H, m), 7.68 (2H, d), 7.44 (1H, s), 7.26-7.10 (4H, m), 4.43 (2H, d), 3.55 (2H, q), 3.41-3.22 (2H, m), 2.89 (2H, t), 2.72-2.60 (1H, m), 2.35 (3H, s), 1.99 (2H, d), 1.65 (2H, d).


MS: APCI(-ve) 450/452 (M-H⁺).

5 m.p. 237-241°C.

Example 29

1-[6-Chloro-5-[[[(2S)-2-phenylpropyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

10



a) 1-[6-Chloro-5-[[[(2S)-2-phenylpropyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester

Prepared according to the method of Example 1(b) using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23(c)) (220 mg) and (βS)-β-methylbenzeneethanamine (150 mg). The resulting solid was recrystallised from acetonitrile to give the sub-title compound (230 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.67 (1H, t), 7.55-7.47 (2H, m), 7.38-7.23 (6H, m), 7.17 (1H, d), 4.40 (2H, d), 4.07 (2H, q), 3.65 (1H, dt), 3.39 (1H, ddd), 3.15-3.01 (3H, m), 2.71-2.62 (1H, m), 1.92 (2H, d), 1.54 (2H, q), 1.28 (3H, d), 1.18 (3H, t).

MS: APCI(+ve) 480/482 (M+H⁺).

b) 1-[6-Chloro-5-[[[(2*S*)-2-phenylpropyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

Prepared according to the method of Example 20(c) using 1-[6-chloro-5-[[[(2*S*)-2-phenylpropyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 29 (a)) (230 mg). The reaction mixture was acidified to pH 5 using 2 M aqueous hydrochloric acid and the solid was collected by filtration and washed with water to give the title compound (160 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (1H, t), 7.58 (1H, d), 7.49 (2H, t), 7.35-7.27 (4H, m), 7.26-7.20 (1H, m), 7.16 (1H, d), 4.33 (2H, d), 3.68-3.59 (1H, m), 3.49-3.40 (1H, m), 3.25-3.06 (3H, m), 2.63-2.53 (1H, m), 1.94 (2H, d), 1.62 (2H, q), 1.30 (3H, d).


MS: APCI(-ve) 450/452 (M-H⁺).

m.p. 150-153°C.

15

Example 30

6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidinyl]-5-quinolinecarboxamide



20

a) 2-Formyl-*N*-[1-(phenylmethyl)-4-piperidinyl]-hydrazinecarboxamide

1-(Phenylmethyl)-4-piperidinamine (3 g) in dichloromethane (10 mL) and triethylamine (4.5 mL) were added dropwise to a stirred solution of triphosgene (1.55 g) in dichloromethane (20 mL) at 0°C under nitrogen. The reaction mixture was allowed to warm to room temperature and stirred for 30 minutes. The mixture was cooled to 0°C and
5 formyl-hydrazine (1.4 g) and triethylamine (4.5 mL) were added. The reaction was stirred at room temperature for 1 hour, then evaporated to dryness. Purification (SiO₂, methanol:dichloromethane:ammonium hydroxide solution 5:95:1 as eluant) gave the sub-title compound (2.5 g).

10 MS: APCI(+ve) 277.2 (M+H⁺).

b) 2,4-Dihydro-4-[1-(phenylmethyl)-4-piperidinyl]-3H-1,2,4-triazol-3-one

2-Formyl-*N*-[1-(phenylmethyl)-4-piperidinyl]-hydrazinecarboxamide (Example 30 (a)) (2.5 g) was divided between 5 10 mL vials. Potassium hydroxide (5 ml, 1 M solution in
15 methanol) was added to each vial and the reactions were heated at 90°C for 35 minutes within a microwave. The combined reaction mixtures were acidified to pH6 with aqueous 2M hydrochloric acid and then evaporated to dryness. Purification (SiO₂, methanol:dichloromethane:acetic acid 15:85:1 as eluant) gave the sub-title compound as an
oil (2.2 g).

20 MS: APCI(+ve) 259.2 (M+H⁺).

c) 2,4-Dihydro-4-(4-piperidinyl)-3H-1,2,4-triazol-3-one

2,4-Dihydro-4-[1-(phenylmethyl)-4-piperidinyl]-3H-1,2,4-triazol-3-one (Example 30(b)) (2.2 g) was divided between 2 10 mL vials. 1,4-Cyclohexadiene (5 mL) and palladium
25 hydroxide (270 mg, 20 wt. % on carbon) were added to each vial and the reactions were heated at 100°C for 30 minutes within a microwave. The reaction mixtures were combined. Ethanol (50 mL) and water (50 mL) were added and the mixture was filtered through diatomaceous earth and evaporated to give sub-title compound as a solid (720 mg).

30 MS: APCI(+ve) 169.2 (M+H⁺).

d) 6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidinyl]-5-quinolinecarboxamide


Prepared according to the method of Example 13, using 2,6-dichloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide (Example 21(c)) (150 mg) and 2,4-dihydro-4-(4-piperidinyl)-3*H*-1,2,4-triazol-3-one (Example 30(c)) (200 mg). Purification (SiO₂, methanol:dichloromethane 2:98 as eluant) gave the title compound as a solid (60 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 11.65 (1H, s), 8.78 (1H, t), 7.97 (1H, s), 7.62-7.39 (5H, m), 7.35-7.26 (3H, m), 4.70 (2H, d), 4.13-4.01 (1H, m), 3.63 (2H, q), 3.12-2.96 (4H, m), 1.94 (2H, d), 1.79 (2H, q).

MS: APCI(+ve) 511/513 (M+H⁺).

Example 31

1-[6-Chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid



a) 1-[6-Chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester

Prepared according to the method of Example 1 using 6-chloro-2-[4-(ethoxycarbonyl)-1-piperidinyl]-5-quinolinecarboxylic acid (Example 23 (c)) (220 mg) and 4-chloro-

benzeneethanamine (200 mg). The resulting solid was recrystallised from acetonitrile to give the sub-title compound (107 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.68 (1H, t), 7.56-7.48 (2H, m), 7.43-7.29 (5H, m), 7.20 (1H, d), 4.41 (2H, d), 4.08 (2H, q), 3.60 (2H, q), 3.11 (2H, t), 2.88 (2H, t), 2.73-2.62 (1H, m), 1.92 (2H, d), 1.55 (2H, q), 1.19 (3H, t).

MS: APCI(+ve) 502 (M+H⁺).

b) 1-[6-Chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid

Prepared according to the method of Example 20 (c) using 1-[6-chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid ethyl ester (Example 31 (a)) (107 mg). The reaction mixture was acidified to pH 5 using 2 M aqueous hydrochloric acid and the solid was collected by filtration and washed with water to give the title compound (80 mg).

¹H NMR (400 MHz, d₆-DMSO) δ 8.45-8.36 (1H, m), 7.64 (1H, d), 7.57 (1H, d), 7.52 (1H, d), 7.37-7.26 (4H, m), 7.22 (1H, d), 4.34 (2H, d), 3.62 (2H, q), 3.23 (2H, t), 2.91 (2H, t), 2.65-2.54 (1H, m), 1.95 (2H, d), 1.64 (2H, q).

MS: APCI(-ve) 470/472 (M-H⁺).

m.p. 231-234°C.

Pharmacological Analysis


Certain compounds such as benzoylbenzoyl adenosine triphosphate (bbATP) are known to be agonists of the P2X₇ receptor, effecting the formation of pores in the plasma membrane (Drug Development Research (1996), 37(3), p.126). Consequently, when the receptor is
5 activated using bbATP in the presence of ethidium bromide (a fluorescent DNA probe), an increase in the fluorescence of intracellular DNA-bound ethidium bromide is observed. The increase in fluorescence can be used as a measure of P2X₇ receptor activation and therefore to quantify the effect of a compound on the P2X₇ receptor.

10 In this manner, each of the title compounds of the Examples was tested for antagonist activity at the P2X₇ receptor. Thus, the test was performed in 96-well flat bottomed microtitre plates, the wells being filled with 250 µl of test solution comprising 200 µl of a suspension of THP-1 cells (2.5×10^6 cells/ml) containing 10^{-4} M ethidium bromide, 25 µl of a high potassium buffer solution containing 10^{-5} M bbATP, and 25 µl of the high
15 potassium buffer solution containing 3×10^{-5} M test compound. The plate was covered with a plastics sheet and incubated at 37 °C for one hour. The plate was then read in a Perkin-Elmer fluorescent plate reader, excitation 520 nm, emission 595 nm, slit widths: Ex 15 nm, Em 20 nm. For the purposes of comparison, bbATP (a P2X₇ receptor agonist) and pyridoxal 5-phosphate (a P2X₇ receptor antagonist) were used separately in the test as
20 controls. From the readings obtained, a pIC₅₀ figure was calculated for each test compound, this figure being the negative logarithm of the concentration of test compound necessary to reduce the bbATP agonist activity by 50%. Each of the compounds of the Examples demonstrated antagonist activity, having a pIC₅₀ figure > 5.5. For example, the following table shows the pIC₅₀ figures for a representative selection of compounds:

Compound of Example No.	pIC ₅₀
1	6.5
3	7.5
11	7.3
20	6.1

CLAIMS

1. A compound of formula



5 or a pharmaceutically acceptable salt or solvate thereof, wherein

p is 0, 1 or 2;

each R^1 independently represents halogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

X is $C(O)NH$ or $NHC(O)$;

10 n is 1, 2, 3, 4 or 5;

within each grouping, CR^5R^6 , R^5 and R^6 each independently represent hydrogen, halogen, phenyl or C_1 - C_6 alkyl, or R^5 and R^6 together with the carbon atom to which they are both attached form a C_3 - C_8 cycloalkyl ring;

R^2 represents an unsaturated 4- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted with at least one substituent selected from halogen, $-COOR^{13}$, hydroxyl, $-NR^{14}R^{15}$, $-CONR^{16}R^{17}$, $-SO_2NR^{18}R^{19}$, $-NR^{20}SO_2R^{21}$, C_1 - C_6 alkyl, C_1 - C_6 alkylcarbonyl, C_1 - C_6 alkoxy, C_1 - C_6 alkylcarbonyloxy, C_1 - C_6 alkoxy carbonyl, C_1 - C_6 hydroxyalkyl and $-S(O)_mC_1$ - C_6 alkyl where m is 0, 1 or 2;

20 R^3 represents hydrogen or a group $-R^7$, $-OR^7$, $-SR^7$ or $-NR^7R^8$;

q is 0, 1 or 2;

each R^4 independently represents halogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

R^7 and R^8 each independently represent hydrogen, C_1 - C_{10} alkyl, C_3 - C_8 cycloalkyl

25 or a saturated or unsaturated 3- to 10-membered heterocyclic ring system comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the alkyl, cycloalkyl and heterocyclic ring system each being optionally substituted with at least one substituent

selected from halogen, hydroxyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ hydroxyalkyl, C₁-C₆ hydroxyalkoxy, C₁-C₆ alkoxycarbonyl, C₃-C₈ cycloalkyl, -NR⁹R¹⁰, -COOR²², -CONR²³R²⁴, -SO₂NR²⁵R²⁶, -NR²⁷SO₂R²⁸ and ZR⁶⁸ or

alternatively, R⁷ and R⁸ may together with the nitrogen atom to which they are

- 5 attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur and that optionally further comprises a bridging group, the heterocyclic ring being optionally substituted with at least one substituent selected from halogen, hydroxyl, cyano, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ hydroxyalkyl, C₁-C₆ hydroxyalkoxy, C₁-C₆ alkoxycarbonyl, C₃-C₈ cycloalkyl, -NR¹¹R¹², -COOR²⁹,
 10 -CONR³⁰R³¹, -SO₂NR³²R³³, -NR³⁴SO₂R³⁵, Z'R⁶⁹, (CH₂)₁₋₆NR⁷⁰R⁷¹, SO₂R⁷², NR⁷³CONR⁷⁴SO₂R⁷⁵ or M(CH₂)₁₋₆COOR⁷⁶ wherein M represents a bond, O, S, SO, SO₂, and a group >NR⁷⁷;

R⁹ and R¹⁰ each independently represent hydrogen or a C₁-C₆ alkylcarbonyl,

- 15 C₂-C₇ alkenyl or C₁-C₇ alkyl group, each group being optionally substituted with at least one substituent selected from hydroxyl, -NR³⁶R³⁷, -COOR³⁸, -CONR³⁹R⁴⁰, -SO₂NR⁴¹R⁴², -NR⁴³SO₂R⁴⁴, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkoxycarbonyl and a saturated or unsaturated 3- to 10-membered ring system which may comprise at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system in turn
 20 being optionally substituted with at least one substituent selected from halogen, hydroxyl, oxo, carboxyl, cyano, C₁-C₆ alkyl and C₁-C₆ hydroxyalkyl, or

alternatively, R⁹ and R¹⁰ may together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring that optionally further comprises one or two ring heteroatoms independently selected from nitrogen, oxygen and
 25 sulphur, the heterocyclic ring being optionally substituted with at least one substituent selected from -OR⁵⁴, -NR⁵⁵R⁵⁶, -(CH₂)_t-NR⁵⁷R⁵⁸ where t is 1, 2, 3, 4, 5 or 6, -COOR⁵⁹, -CONR⁶⁰R⁶¹, -SO₂NR⁶²R⁶³, -NR⁶⁴SO₂R⁶⁵, C₁-C₆ hydroxyalkyl, C₁-C₆ alkoxy, C₁-C₆ alkylthio, C₁-C₆ alkoxycarbonyl and Z''R⁸⁰;

R¹¹ and R¹² each independently represent hydrogen or a C₁-C₆ alkylcarbonyl, C₁-

- 30 C₆ alkoxycarbonyl, C₂-C₇ alkenyl or C₁-C₇ alkyl group, each group being optionally

substituted with at least one substituent selected from hydroxyl, $-NR^{45}R^{46}$, $-COOR^{47}$, $-CONR^{48}R^{49}$, $-SO_2NR^{50}R^{51}$, $-NR^{52}SO_2R^{53}$, $-NR^{66}C(O)R^{67}$, C_1 - C_6 alkoxy, C_1 - C_6 alkylthio and C_1 - C_6 alkoxycarbonyl;

Z , Z' and Z'' independently represent a bond, O, S, SO, SO_2 , $>NR^{78}$, C_{1-6} alkylene,

5 or a group $-O(CH_2)_{1-6}$, $-NR^{79}(CH_2)_{1-6}$ or $-S(O)_p(CH_2)_{1-6}$ wherein p is 0, 1 or 2;

R^{68} , R^{69} and R^{80} independently represent tetrazolyl or a 5- to 6- membered heterocyclic ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which heterocyclic ring is substituted by at least one substituent selected from hydroxyl, $=O$, and $=S$, and which heterocyclic ring may further be optionally substituted
10 by at least one substituent selected from halogen, nitro, cyano, $-SO_2C_{1-6}$ alkyl, C_{1-6} alkoxycarbonyl, and a C_{1-6} alkyl group which C_{1-6} alkyl group can be optionally substituted by at least one substituent selected from halogen and hydroxyl;

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{20} and R^{21} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl,

15 halogen and C_1 - C_6 alkoxy;

R^{22} , R^{23} , R^{24} , R^{25} , R^{26} , R^{27} , R^{28} , R^{29} , R^{30} , R^{31} , R^{32} , R^{33} , R^{34} and R^{35} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

R^{36} , R^{37} , R^{38} , R^{39} , R^{40} , R^{41} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} , R^{47} , R^{48} , R^{49} , R^{50} , R^{51} , R^{52}
20 and R^{53} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

R^{54} , R^{55} , R^{56} , R^{57} , R^{58} , R^{59} , R^{60} , R^{61} , R^{62} , R^{63} , R^{64} , R^{65} , R^{66} and R^{67} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy; and

25 R^{70} , R^{71} , R^{72} , R^{73} , R^{74} , R^{75} , R^{76} , R^{77} , R^{78} and R^{79} each independently represent hydrogen or C_1 - C_6 alkyl optionally substituted by at least one substituent selected from hydroxyl, halogen and C_1 - C_6 alkoxy;

with the provisos that:

- (a) when X represents NHC(O) , p is 0, q is 0, n is 1 and R^3 , R^5 and R^6 each independently represent hydrogen, then R^2 is other than a 2-carboxy-phenyl group; and
- (b) when X represents NHC(O) , p is 0, q is 0, n is 2, R^3 represents hydrogen and each R^5 and R^6 independently represents hydrogen, then R^2 is other than a 3,4-diamino-phenyl group or a 5-methyl-2-furanyl group; and
- (c) when X represents C(O)NH , p is 0, q is 0, n is 2, R^3 represents hydrogen and each R^5 and R^6 independently represents hydrogen, then R^2 is other than an unsubstituted phenyl group, an unsubstituted 1H-indol-3-yl group, or a 2-methyl-1H-indol-3-yl group.
2. A compound according to claim 1, wherein X is NHC(O) .
3. A compound according to claim 1 or claim 2, wherein R^2 represents an unsaturated 4-, 5- or 6-membered ring optionally comprising one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring being optionally substituted with one, two, three or four substituents independently selected from halogen, $-\text{COOR}^{13}$, hydroxyl, $-\text{NR}^{14}\text{R}^{15}$, $-\text{CONR}^{16}\text{R}^{17}$, $-\text{SO}_2\text{NR}^{18}\text{R}^{19}$, $-\text{NR}^{20}\text{SO}_2\text{R}^{21}$, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_1\text{-C}_4$ alkylcarbonyl, $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_4$ alkylcarbonyloxy, $\text{C}_1\text{-C}_4$ alkoxycarbonyl, $\text{C}_1\text{-C}_4$ hydroxyalkyl and $-\text{S(O)}_m\text{C}_1\text{-C}_4$ alkyl where m is 0, 1 or 2.
4. A compound according to any one of the preceding claims, wherein R^3 represents hydrogen or a group $-\text{R}^7$ or $-\text{NR}^7\text{R}^8$.
5. A compound according to any one of the preceding claims wherein R^7 and R^8 each independently represent hydrogen or $\text{C}_1\text{-C}_{10}$ alkyl optionally substituted with one or two substituents independently selected from halogen, hydroxyl, $\text{C}_1\text{-C}_4$ alkoxy, $\text{C}_1\text{-C}_4$ alkylthio, $\text{C}_1\text{-C}_4$ hydroxyalkyl, $\text{C}_1\text{-C}_4$ hydroxyalkoxy, $\text{C}_1\text{-C}_4$ alkoxycarbonyl, $\text{C}_5\text{-C}_6$ cycloalkyl, $-\text{NR}^9\text{R}^{10}$, $-\text{COOR}^{22}$, $-\text{CONR}^{23}\text{R}^{24}$, $-\text{SO}_2\text{NR}^{25}\text{R}^{26}$ and $-\text{NR}^{27}\text{SO}_2\text{R}^{28}$.

6. A compound according to any one of claims 1 to 4, wherein R^7 and R^8 together with the nitrogen atom to which they are attached form a 5- to 6-membered saturated heterocyclic ring that optionally further comprises a ring nitrogen atom, the heterocyclic ring being optionally substituted with one or two substituents independently selected from halogen, hydroxyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylthio, C_1 - C_4 hydroxyalkyl, C_1 - C_4 hydroxyalkoxy, C_1 - C_4 alkoxycarbonyl, C_5 - C_6 cycloalkyl, $-NR^{11}R^{12}$, $-COOR^{29}$, $-CONR^{30}R^{31}$, $-SO_2NR^{32}R^{33}$ and $-NR^{34}SO_2R^{35}$.
7. A compound according to any one of the preceding claims, wherein within each grouping CR^5R^6 , R^5 and R^6 each independently represent hydrogen or C_1 - C_4 alkyl.
8. A compound according to claim 1 selected from:
- 6-Chloro-2-methyl-*N*-[(2*R*)-2-phenylpropyl]-5-quinolinecarboxamide,
- 6-Chloro-2-methyl-*N*-[(2*S*)-2-phenylpropyl]-5-quinolinecarboxamide,
- (βR)-*N*-[6-Chloro-2-[methyl[3-(methylamino)propyl]amino]-5-quinolinyl]- β -methyl-benzenepropanamide,
- (βR)-*N*-[6-Chloro-2-(1-piperazinyl)-5-quinolinyl]- β -methyl-benzenepropanamide,
- 6-Chloro-2-methyl-*N*-(2-phenylethyl)-5-quinolinecarboxamide,
- (βR)-*N*-[6-Chloro-2-[3-(ethylamino)propyl]-5-quinolinyl]- β -methyl-benzenepropanamide,
- (βR)-*N*-[6-Chloro-2-[3-[(3-hydroxypropyl)amino]propyl]-5-quinolinyl]- β -methyl-benzenepropanamide,
- 3,4-Dichloro- α -methyl-*N*-5-quinolinyl-benzenepropanamide,
- (βR)-*N*-[6-Chloro-2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]- β -methyl-benzenepropanamide,
- 2-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,
- 2,4-Dichloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,
- 4-Chloro-*N*-[6-chloro-2-(1-piperazinyl)-5-quinolinyl]-benzenepropanamide,

(βR)-*N*-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinoliny]- β -methyl-benzenepropanamide,

N-[6-Chloro-2-(1-piperazinyl)-5-quinoliny]-2-methoxy-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(3-hydroxypropyl)amino]-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide,

(βR)-*N*-[6-Chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinoliny]- β -methyl-benzenepropanamide,

N-[6-Chloro-2-(1-piperazinyl)-5-quinoliny]-benzenepropanamide,

N-[2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-5-quinoliny]-2-chloro-benzenepropanamide,

2-Chloro-*N*-[6-chloro-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinoliny]-benzenepropanamide,

1-[6-Chloro-5-[[3-(2-chlorophenyl)-1-oxopropyl]amino]-2-quinoliny]-4-piperidinecarboxylic acid,

2-[(3*S*)-3-Amino-1-pyrrolidinyl]-6-chloro-*N*-[2-(2-chlorophenyl)ethyl]-5-quinolinecarboxamide,

6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[(3*S*)-3-[(2-hydroxyethyl)amino]-1-pyrrolidinyl]-5-quinolinecarboxamide,

1-[6-Chloro-5-[[[2-(2,6-dichlorophenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2,2-diphenylethyl)amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-phenylethyl)amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-fluorophenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,

1-[6-Chloro-5-[[[2-(2-methylphenyl)ethyl]amino]carbonyl]-2-quinoliny]-4-piperidinecarboxylic acid,


1-[6-Chloro-5-[[[(2*S*)-2-phenylpropyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,

6-Chloro-*N*-[2-(2-chlorophenyl)ethyl]-2-[4-(1,5-dihydro-5-oxo-4*H*-1,2,4-triazol-4-yl)-1-piperidinyl]-5-quinolinecarboxamide, and

- 5 1-[6-Chloro-5-[[[2-(4-chlorophenyl)ethyl]amino]carbonyl]-2-quinolinyl]-4-piperidinecarboxylic acid,
and all their pharmaceutically acceptable salts and solvates.

- 10 9. A process for the preparation of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, which comprises

(a) reacting a compound of formula




- 15 wherein L^1 represents a leaving group (e.g. hydroxyl or halogen) and p , q , R^1 , R^3 and R^4 are as defined in formula (I), with a compound of formula



wherein n , R^2 , R^5 and R^6 are as defined in formula (I); or

- 20 (b) reacting a compound of formula




wherein p , q , R^1 , R^3 and R^4 are as defined in formula (I), with a compound of formula



wherein L^2 represents a leaving group (e.g. hydroxyl or halogen) and n , R^2 , R^5 and R^6 are
25 as defined in formula (I); or


above, followed by an oxidation reaction and then by reaction with a compound of formula (XI) as defined in (e) above under reductive amination conditions; or

- (g) when R^3 represents a group R^7ZR^{68} or NR^7R^8 wherein R^7 and/or R^8 are substituted by a group $Z'R^{69}$ or R^7 and R^8 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring substituted by a group $Z'R^{69}$, and R^{68} or R^{69} is tetrazolyl, reacting a group of formula (XII) or (XIII)




with a compound of formula GN_3 , wherein G is sodium, a trialkylsilyl, an alkyltin or ammonium, to yield a group of formula I wherein R^7 , R^8 , Z, Z' are as defined in formula (I); or

- (h) when R^3 represents a group R^7ZR^{68} or NR^7R^8 wherein R^7 and/or R^8 are substituted by a group $Z'R^{69}$ or R^7 and R^8 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring substituted by a group $Z'R^{69}$, and R^{68} or R^{69} is group of formula




reacting a compound of formula XII or XIII wherein XII or XIII are as defined in (g) above with hydroxylamine, followed by treatment with 1,1'-thiocarbonyldiimidazole and subsequent treatment with silica gives a group of formula (XIV) wherein J is S, alternatively reacting a compound of formula XII or XIII wherein XIII or XIII are as defined in (g) above with hydroxylamine, followed by treatment with a suitable chloroformate gives a group of formula (XIV) wherein J is O; or

(i) when R^3 represents a group R^7ZR^{68} or NR^7R^8 wherein R^7 and/or R^8 are substituted by a group $Z'R^{69}$ or R^7 and R^8 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclic ring substituted by a group $Z'R^{69}$, and R^{68} or R^{69} is



reacting a compound of formula XVI or XVII



with a source of phosgene followed by treatment with formyl hydrazine and subsequent treatment with base;

and optionally after (a), (b), (c), (d), (e), (f), (g), (h) or (i) carrying out one or more of the following:

- converting the compound obtained to a further compound of the invention
- forming a pharmaceutically acceptable salt or solvate of the compound.

10. A compound of formula (VI) as defined in claim 9.

11. (βR) - N -(2,6-Dichloro-5-quinoliny)- β -methyl-benzenepropanamide.

12. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

13. A process for the preparation of a pharmaceutical composition as claimed in claim 12 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as defined in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.

14. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 for use in therapy.

5 15. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment of rheumatoid arthritis.

16. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate
10 thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment of an obstructive airways disease.

17. Use according to claim 16, wherein the obstructive airways disease is asthma or chronic obstructive pulmonary disease.

15

18. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment of osteoarthritis.

20 19. Use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment of atherosclerosis.

20. A method of treating rheumatoid arthritis or osteoarthritis which comprises
25 administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

21. A method of treating an obstructive airways disease which comprises administering to a patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as claimed in any one of claims 1 to 8.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001144

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 215/38, C07D 215/48, C07D 403/04, A61K 31/47, A61K 31/4709,
A61K 31/497, A61P 9/10, A61P 11/00 A61P 29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, STN-CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5804588 A (DYKE ET AL), 8 Sept 1998 (08.09.1998), formula I --	1-21
X	S D. Sharma, Usha Mehra, S B Pandhi, JPS Khurana, Studies of Fused Beta-Lactams: Synthesis & Antibacterial Activity of Some Pyridyl/Quinolyl-2-azetidiones, Indian Journal of Chemistry, Vol. 27B, May 1998, pages 494-497, compound VI --	1-21
A	Tiziana Modena, Ida Genta, Marco Mazza, "Plant Growth Regulating Activities of 2-[2-(Arylamino)-2-oxoethyl]benzoic acids", IL FARMACO, Vol. 48, No. 4, 1993, pages 567-572, tables I-III --	1-21

☒ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 November 2004

Date of mailing of the international search report

17 -11- 2004

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

FERNANDO FARIETA/BS

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 2004/001144

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0501656 A2 (SANKYO COMPANY LIMITED), 2 Sept 1992 (02.09.1992), formula I --	1-21
A	EP 0940391 A2 (SMITHKLINE BEECHAM FARMACEUTICI S.P.A.), 8 Sept 1999 (08.09.1999), formula I --	1-21
A	WO 9719926 A1 (SMITHKLINE BEECHAM S.P.A.), 5 June 1997 (05.06.1997), formula I -- -----	1-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/001144

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **20-21**
because they relate to subject matter not required to be searched by this Authority, namely:
see extra sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2004/001144

Box II.1

Claims 20-21 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

INTERNATIONAL SEARCH REPORT

information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001144

US	5804588	A	08/09/1998	AU	722472	B	03/08/2000
				AU	722662	B	10/08/2000
				AU	2905897	A	09/12/1997
				AU	2905997	A	09/12/1997
				BR	9709015	A	03/08/1999
				BR	9709105	A	03/08/1999
				CA	2252501	A	27/11/1997
				CA	2252531	A	27/11/1997
				CN	1219131	A	09/06/1999
				CN	1219168	A	09/06/1999
				CZ	9803651	A	17/03/1999
				EP	0912519	A	06/05/1999
				EP	0952832	A	03/11/1999
				GB	9610506	D	00/00/0000
				IL	126557	A	12/09/2002
				JP	2000510865	T	22/08/2000
				JP	2000510866	T	22/08/2000
				NO	312099	B	18/03/2002
				NO	985376	A	19/11/1998
				NZ	332341	A	26/05/2000
				PL	329922	A	26/04/1999
				RU	2170730	C	20/07/2001
				SK	160598	A	10/12/1999
				SK	283162	B	04/03/2003
				TR	9802385	T	00/00/0000
				US	5834485	A	10/11/1998
				WO	9744036	A	27/11/1997
				WO	9744322	A	27/11/1997
				ZA	9704373	A	20/05/1998
				ZA	9704374	A	20/05/1998
				GB	9623234	D	00/00/0000
				GB	9626883	D	00/00/0000
				GB	9708072	D	00/00/0000

EP	0501656	A2	02/09/1992	SE	0501656	T3	
				AT	148098	T	15/02/1997
				CA	2061557	A	22/08/1992
				CN	1036064	B	08/10/1997
				CN	1064273	A	09/09/1992
				CZ	9200500	A	17/03/1993
				DE	69216873	D,T	21/08/1997
				DK	501656	T	21/07/1997
				ES	2099206	T	16/05/1997
				GR	3022594	T	31/05/1997
				HK	1005722	A	00/00/0000
				HU	64012	A	29/11/1993
				HU	9200579	D	00/00/0000
				IE	920538	A	26/08/1992
				JP	2561809	Y	04/02/1998
				JP	4117860	U	21/10/1992
				JP	5112515	A	07/05/1993
				RU	2042663	C	27/08/1995
				US	5614521	A	25/03/1997
				US	5643925	A	01/07/1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001144

EP	0940391	A2	08/09/1999	SI	804419	T	00/00/0000
				AP	578	A	26/03/1997
				AP	9500745	D	00/00/0000
				AT	246677	T	15/08/2003
				AT	273959	T	15/09/2004
				AU	699319	B	03/12/1998
				AU	1216299	A	25/03/1999
				AU	2616495	A	21/12/1995
				BG	64004	B	30/09/2003
				BG	101008	A	29/08/1997
				BG	103181	A	30/09/1999
				BR	9507788	A	23/09/1997
				CA	2191352	A,C	07/12/1995
				CA	2257662	A	07/12/1995
				CN	1092642	B	16/10/2002
				CN	1156451	A	06/08/1997
				CN	1276211	A	13/12/2000
				CN	1428145	A	09/07/2003
				CZ	291476	B	12/03/2003
				CZ	9603470	A	15/10/1997
				DE	69531458	D,T	05/08/2004
				DE	69533408	D	00/00/0000
				DK	804419	T	24/11/2003
				EP	0804419	A,B	05/11/1997
				SE	0804419	T3	
				ES	2204952	T	01/05/2004
				FI	964712	A	23/01/1997
				FI	990268	A	10/02/1999
				HK	1003884	A	00/00/0000
				HU	76286	A	28/07/1997
				HU	9603262	D	00/00/0000
				HU	9900343	D	00/00/0000
				IL	113844	D	00/00/0000
				IL	126806	D	00/00/0000
				IL	128220	D	00/00/0000
				IL	139301	D	00/00/0000
				IT	MI941099	A	27/11/1995
				JP	10500697	T	20/01/1998
				JP	2000026314	A	25/01/2000
				JP	2002179594	A	26/06/2002
				MA	23560	A	00/00/0000
				NO	307783	B	29/05/2000
				NO	965036	A	24/01/1997
				NO	991813	A	24/01/1997
				NZ	287442	A	27/05/1998
				NZ	329979	A	28/07/2000
				OA	10592	A	27/08/2002
				PL	186075	B	31/10/2003
				PL	186665	B	27/02/2004
				PL	317381	A	01/04/1997
				PT	804419	T	31/12/2003
				RO	114445	A,B	30/04/1999
				RU	2155754	C	10/09/2000
				SK	4799	A	11/06/1999
				SK	151496	A	09/07/1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

30/10/2004

International application No.

PCT/SE 2004/001144

EP	0940391	A2	08/09/1999	SK	282721 B	06/11/2002
				SK	282722 B	06/11/2002
				TW	427977 B	00/00/0000
				TW	533199 B	00/00/0000
				US	5811553 A	22/09/1998
				US	6608083 B	19/08/2003
				US	20030236281 A	25/12/2003
				WO	9532948 A	07/12/1995
				ZA	9504269 A	14/05/1996
				IT	237026 Y	31/08/2000
				IT	1293558 B	01/03/1999
				IT	MI950494 A,U,V	16/09/1996

WO	9719926	A1	05/06/1997	AP	9801238 D	00/00/0000
				AU	1031897 A	19/06/1997
				BG	102557 A	31/03/1999
				BR	9611757 A	06/04/1999
				CA	2238328 A	05/06/1997
				CN	1207729 A	10/02/1999
				CZ	9801580 A	14/10/1998
				EA	1771 B	00/00/0000
				EP	1019377 A	19/07/2000
				HU	9901016 A	28/03/2000
				IL	124418 D	00/00/0000
				IT	1276171 B	27/10/1997
				IT	MI952462 A	26/05/1997
				JP	2000513325 T	10/10/2000
				MA	24011 A	00/00/0000
				NO	311213 B	29/10/2001
				NO	982333 A	22/07/1998
				OA	11011 A	06/03/2003
				PL	326928 A	09/11/1998
				SK	66898 A	02/12/1998
				TR	9800883 T	00/00/0000
				TW	409123 B	00/00/0000
				US	20020068827 A	06/06/2002
				ZA	9609811 A	22/05/1998
				ID	16747 A	00/00/0000
				IT	1307330 B	30/10/2001
				IT	MI961688 A	02/02/1998
				NZ	323388 A	28/01/2000